Future MICROBIOLOGY



RESEARCH ARTICLE

For reprint orders, please contact: reprints@futuremedicine.com

Immunoreactivity of synthetic peptides derived from proteins of *Cryptococcus gattii*

Rafael Melo Santos de Serpa Brandão[1], Liline Maria Soares Martins[1,2], Hélida Monteiro de Andrade[3], Angélica Rosa Faria[3], Maria José Soares Leal[4], Adalberto Socorro da Silva[5], Bodo Wanke[6], Márcia dos Santos Lazéra[6], Marilene Henning Vainstein[7], Rinaldo Poncio Mendes[8], Daniela Vanessa Moris[8], Ricardo de Souza Cavalcante[9] & Semiramis Jamil Hadad do Monte*[,10]

ABSTRACT: **Aim:** To determine the immunoreactivity of synthetic *Cryptococcus*-derived peptides. **Materials & methods:** A total of 63 B-cell epitopes from previously identified *Cryptococcus gattii* immunoreactive proteins were synthesized and evaluated as antigens in ELISAs. The peptides were first evaluated for their ability to react against sera from immunocompetent subjects carrying cryptococcal meningitis. Peptides that yielded high sensitivity and specificity in the first test were then retested with sera from individuals with other fungal pathologies for cross-reactivity determination. **Results:** Six of 63 synthetic peptides were recognized by antibodies in immunoassays, with a specificity of 100%, sensitivity of 78% and low cross-reactivity. **Conclusion:** We successfully determined the immunoreactivity of selected synthetic peptides of *C. gattii* derived proteins.

KEYWORDS
• antigens • cryptococcosis
• diagnosis • ELISA
• synthetic peptides

Cryptococcosis is an important mycosis that affects humans and animals worldwide. *Cryptococcus neoformans* and *C. gattii* are the main pathogens that infect humans. *C. neoformans* mainly affects immunocompromised hosts, whereas *C. gattii* usually affects immunocompetent hosts [1,2]. Globally, almost 1 million cases of cryptococcal meningitis in HIV-infected subjects are estimated to occur every year, causing over 600,000 deaths [3]. *C. gattii* merits special attention because an outbreak has already occurred on Vancouver Island and has been shown to have spread rapidly to the Pacific coast of Canada and the USA [4–6].

Cryptococcosis is not a disease of compulsory notification in Brazil, thus surveillance for this mycosis does not exist. Its prevalence and annual incidence can only be roughly estimated through reports of cases by specialized services. Nevertheless, it is well known that the clinical cases caused by the

[1]Laboratório de Imunogenética e Biologia Molecular, Universidade Federal do Piauí, Campus Ministro Petrônio Portella Bloco, Piauí, Brasil
[2]Faculdade de Ciências Médicas da Universidade Estadual do Piauí, Piauí, Brasil
[3]Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Minas Gerais, Brasil
[4]Universidade Federal do Piauí, Campus Ministro Petrônio Portella, Piauí, Brasil
[5]Laboratório de Imunogenética e Biologia Molecular, Universidade Federal do Piauí, Campus Ministro Petrônio Portella Bloco, Piauí, Brasil
[6]Laboratório de Micologia, Instituto Nacional de Infectologia Evandro Chagas-INI - Fundação Oswaldo Cruz-FIOCRUZ, Rio de Janeiro, Brasil
[7]Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Porto Alegre Rio Grande do Sul, Brasil
[8]Departamento de Doenças Tropicais, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, Brasil
[9]Departamento de Doenças Tropicais e Diagnóstico por Imagem, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, Brasil
[10]Laboratório de Imunogenética e Biologia Molecular, Universidade Federal do Piauí, Campus Ministro Petrônio Portella Bloco, Piauí, Brasil
*Author for correspondence: libufpi@gmail.com

Future Medicine part of fsg

Table 1. Synthetic peptides derived from immunoreactive proteins of *Cryptococcus gattii* and the amino acid sequences.

Peptide name	Protein	Amino acid sequence
S4	sks2	VIDKDGSPYVEVDY
S13	sks2	PVYEGERTQCKDNR
H18	Hsp70	VDVNGEIGVKVNYL
H21	Hsp70	RHFGGRDFDYALVQ
H24	Hsp70	KEAGNPDEDTELVV
H26	Hsp70	EASYADPATLPKGI
H27	Hsp70	EEEVTVGEGEDAKT
H30	Hsp70	EEGEDASKSAYVQK
G36	GrpE	TALKHVPQPIPAEN
E43	ENO1	SIEDPFHEDDFDAW
Hy49	CGNB 1302	PEAKSGGASANETA
Hy50	CGNB 1302	QKSANANKGEEKTE
X56	CGNB 1079	SQNQGYGQQPGGYG
X57	CGNB 1079	GGYGQQENYGGQNQ

two species of *Cryptococcus* are differently distributed throughout Brazil. *C. neoformans* predominates in all regions of the country and infects mainly immunocompromised hosts, especially AIDS patients; *C. gattii* (mainly genotype VGII) predominates in the northern and northeastern regions in immunocompetent adults, adolescents and children, with high morbidity and mortality rates, ranging from 37 to 49% [7–11].

The diagnosis of cryptococcosis is attained through microscopy, culture followed by biochemical tests and the detection of cryptococcal capsular antigen by enzyme immunoassay, latex agglutination or lateral flow assay [12–14]. The lateral flow assay is increasingly used in the cryptococcosis diagnosis, and it is widely used in sub-Saharan Africa and its performance has been widely shown in immunosuppressed patients and insufficiently reported in immunocompetent patients [15,16]. In this scenario, some gaps remain to be filled as detection of subclinical forms, differential diagnosis of species, among others.

Using immunoproteomics and bioinformatics approaches, Martins *et al.* identified B-cell epitopes with antigenic and/or immunogenic potential [17]. The application of synthetic peptides aiming to improve the diagnosis and development of vaccines for infectious diseases has been reported, but little has been achieved with regard to systemic mycoses [18]. This methodology has demonstrated a potential for discovering antigenic targets in leishmaniasis, Chagas disease, paracoccidioidomycosis and tuberculosis [18–23]. In this study, new antigenic targets for diagnostic tests for cryptococcosis were evaluated using synthetic peptides obtained from immunoreactive proteins of *C. gattii*.

Materials & methods

• Study population

Serum specimens from ten healthy individuals and 138 patients, comprising 70 with cryptococcosis, 17 with coccidioidomycosis, 22 with paracoccidioidomycosis, six with histoplasmosis, eight with aspergillosis and 15 with

Table 2. Diagnostic performance of synthetic peptides in serum samples from 70 cryptococcosis patients and ten healthy individuals with the respective immunoassay accuracy values.

Peptides	Sp	Se	AUC	Youden Index J	Cut-off	p-value
S4	90.00	61.43	0.780	0.5143	0.1193	0.0001
H18	90.00	60.00	0.757	0.5000	0.0583	<0.0001
H21	100.00	78.57	0.873	0.7857	0.0632	<0.0001
H26	90.00	60.00	0.750	0.5000	0.0666	0.0004
Hy49	90.00	70.00	0.786	0.6000	0.0751	<0.0001
Hy50	100.00	55.71	0.700	0.5571	0.0948	0.0007

The cut-off points were performed using Youden Index J.
AUC: Area under the curve; Se: Sensitivity; Sp: Specificity.

sporotrichosis, were included in this study, as shown in **Supplementary Table 1** (see online at www.futuremedicine.com/doi/suppl/10.2217/fmb.14.49).

• Synthetic peptides

Synthetic peptides were derived from the mapping of B-cell epitopes of immunoreactive proteins of *C. gattii* (genotype VGII) identified from an immunoproteomics approach. Only peptides that were simultaneously identified by the ABCpred and BCpreds programs were considered to be putative antigens for immunoassays for cryptococcosis [17].

A total of 63 overlapping peptides (20 mer amino acids, with an overlap of 14 amino acids) covering six immunogenic *C. gattii* proteins (Hsp70, sks2, GrpE, enolase, conserved hypothetical protein CGNB 1302 and conserved hypothetical protein CGNB 1079) were synthesized (PEPTIDE 2.0, Chantilly, VA, USA; **(Supplementary Table 2)** [37]. Experiments were previously approved by the Human Ethics Committee at the State University of Piauí under protocol number 079/2008.

• ELISA

First, we optimized the ELISA reaction with optimal peptide concentrations (20 μg/ml), serum dilution (1:200) and conjugated immunoglobulins (1:10.000). Using these parameters, we had a better separation between the cryptococcosis patient's serum and uninfected individuals.

Briefly, Falcon flexible microtiter plates (Becton Dickinson, France) were coated with 100 μl/well of synthetic peptides diluted in bicarbonate buffer overnight at 4°C. The synthetic peptides were then blocked with 5% powdered skim milk in PBS-Tween20 (0.05%; PBST) for 1 h at 37°C. Serum samples diluted in PBST-milk (0.5%) were added to the wells for 1 h at 37°C. The plates were washed three-times with PBST, and diluted peroxidase-conjugated anti-human immunoglobulin G with PBST-milk (0.5%) was added. Subsequently, the micro-plates were incubated for 1 h at 37°C and washed three-times with PBST; the enzyme substrate Fast-OPD™ (Sigma-Aldrich, St Louis, MO, USA) was then added. The plates were incubated for 30 min in the dark at room temperature. The reactions were stopped with 2 M H_2SO_4, and the absorbance was measured at 492 nm using a Multiskan Plate Reader (MCC/340; Thermo Fisher Scientific, MA, USA).

Once the ELISA reaction was optimized, all peptides were screened for reactivity with separate pools of sera from ten cryptococcosis subjects with *C. gattii* infection and ten healthy individuals. The peptides that produced a high optical density (OD) difference between the cryptococcosis subjects and controls were considered potential candidate antigens for further assays using individual serum from infected (n = 70) and healthy (n = 10) subjects. As there was no OD difference ($p > 0.05$) between the serum from subjects infected by *C. gattii* and



Figure 1. Immunoreactivity of 63 synthetic peptides derived from immunoreactive proteins of *Cryptococcus gattii* with a pool of sera from ten cryptococcosis patients (+) and a pool of sera from ten healthy individuals (-).


A
H21
Absorbance 492 nm
1.0
0.8
0.6
0.4
0.2
Cut off
0.0
Negative control
Cryptococcosis
Coccidioidomycosis
Paracoccidioidomycosis
Histoplasmosis
Aspergillosis
Sporotrichosis
B
Hy49
C
S4
D
H18
E
H26
1.4
1.2
F
Hy50

Figure 2. ELISA reactivity of the sera from subjects with cryptococcosis and other fungal infections against peptides (see facing page). (A) H21, **(B)** Hy49, **(C)** S4, **(D)** H18, **(E)** H26 and **(F)** Hy50. ELISA was performed with sera from ten healthy subjects and 138 patients with different fungal infections: 70 with cryptococcosis; 17 with coccidioidomycosis; 22 with paracoccidioidomycosis; six with histoplasmosis; eight with aspergillosis; and 15 with sporotrichosis. The samples were tested against six synthetic peptides derived from immunoreactive proteins of *Cryptococcus gattii*.

C. neoformans, analyses were performed by combining these sera in the cryptococcosis group. In this phase, those peptides with a sensitivity and specificity that were on average greater than or equal to 70% were evaluated for crossreactivity patterns against the subjects infected with other fungal diseases, as reported above. All samples (n = 148) were analyzed by the mean value of triplicate reactions.

• Statistical analysis

For each peptide, the sensitivity and specificity was determined by means of receiver operating characteristic curve analysis. The accuracy of each test was evaluated according to the area under the curve (AUC), as follows: no value (AUC = 0.5), low accuracy (0.5 < AUC < 0.7), moderate accuracy (0.7 < AUC < 0.9), high accuracy (0.9 < AUC < 1.0) and a perfect test (AUC = 1). Additionally, the Youden Index (J) [24] was used to choose the best cut-off point of each peptide for the healthy subjects and all fungal pathology tests. J has been defined as the accuracy of a test in clinical epidemiology and shows the point of the curve with the least chance of being random [25,26].

All statistical analyses were performed using GraphPad Prism™ (version 6.0) and MedCalc™ (version 11.5.0). A p-value of <0.05 was considered statistically significant.

Results

Figure 1 shows the OD observed between a pool of sera from cryptococcosis subjects and a pool of sera from negative controls against the 63 synthetic peptides tested in the screening. A total of 14 peptides **(Table 1)** showed an OD difference above 0.04 and were retested with individual serum. This cut-off was the smallest OD difference able to distinguish cryptococcosis patients from negative controls.

The receiver operating characteristic curve analysis showed that six of the 14 peptides (S4, H18, H21, H26, Hy49 and Hy50) had high sensitivity and specificity. All of them were considered to have moderate accuracy (0.7 < AUC < 0.9) **(Table 2)**. The best recognized peptide was H21 (sensitivity 79% and specificity 100%), followed by Hy49 (sensitivity 70% and specificity 90%). These results were confirmed by the Youden Index (H21 = 0.7857; Hy49 = 0.60). **Table 2** summarizes the AUC data and the Youden Index.

The analysis of cross-reactivity based on the cutoffs obtained by the Youden Index showed that the peptides tested are recognized chiefly by the antisera from cryptococcosis patients. The recognition by antibodies of sera from patients with other fungal diseases was found to be heterogeneous, with OD values much lower than those observed for cryptococcosis (p-values ranging from $p < 0.0001$ to $p = 0.0007$), with the exception of H18 **(Figure 2)**.

Approaching the theoretical additive reactivities of the six peptides (S4, H18, H21, H26, HP49 and Hy50) showed that the association of five peptides (S4, H18, H21, H26 and HP49) improved the test accuracy to a high level (AUC = 0.9143 and IJ = 0.8143), as shown in **Table 3**. With this combination of peptides, the specificity is 100%, and the sensitivity increased to 81.4%.

Discussion

Efforts for a diagnostic test for cryptococcosis have advanced in the last years. The focus of these tests is the search for cryptococcal antigens. This work shows a new approach of diagnosis aiming at the detection of antibodies.

Here, we report the validation of the immunoproteomics approach as a strategy to identify new antigenic targets for the development of diagnostic tests for cryptococcosis. We studied 63 peptides derived from six proteins. Six peptides were identified as good antigenic candidates for developing new diagnostic tests for cryptococcosis. Of these, three are derived from Hsp70 (H18, H21 and H26). This chaperone possesses both regions conserved during evolution and variable regions that allow a distinction between species [27], and it may present immunogenic epitopes. In fact, recent works have characterized Hsps as key antigens inducing humoral responses to *C. neoformans* and *C. gattii* [17,28,29]. Furthermore, Rodrigues *et al.* [30] reported that Hsps are secreted by extracellular

Table 3. Theoretical additive reactivities with several combinations of peptides derived from immunoreactive proteins of *Cryptococcus gattii*.

Peptide combination	Area under the curve
H21 + Hy49 + S4 + H18 + H26 + Hy50	0.8186
H21 + Hy49 + S4 + H18 + H26	0.9143
H21 + Hy49 + S4 + H18	0.8486
H21 + Hy49 + S4	0.8543
H21 + Hy49	0.8557
H21	0.8730

vesicles and that these vesicles are involved in cryptococcal pathogenesis. Recently, Silveira *et al.* [31] showed the involvement of Hsp70 in the adhesion and phagocytosis processes of *C. neoformans*.

The remaining peptides are derived from two proteins for which information in the literature is scarce: peptides Hy49 and Hy50 (hypothetical protein CGNB 1302) and peptide S4 (protein Sks2) [17].

The cross-reactivity pattern between the sera of individuals with cryptococcosis and other fungal infections observed may be explained, at least in part, by the high homology between the sequences of the proteins studied [17]. However, the recognition of antibodies from patients carrying other mycoses by the peptides analyzed resulted in low ODs when compared with the ODs using samples from cryptococcosis patients (p value ranged from $p < 0.0001$ to $p = 0.0007$), except for H18. Houghton *et al.* [32] and Khan *et al.* [33] showed that further optimization by constructing chimerical multiepitope peptides or peptides attached to multiplexed microbeads may help in the accuracy of immunoassays. Our theoretical additive reactivities were similar, corroborating studies in other pathologies [19,21,22,34].

The peptides studied are promising, as they showed a satisfactory specificity, being a good starting point for further studies in clinical practice, as it can exclude other morbidities with similar clinical manifestations. In addition, the search for an alternative to diagnose cryptococcosis in advance, together with the lack of studies using synthetic peptides in developing serological tests in mycoses, makes the validation of synthetic peptides for developing a diagnostic test of cryptococcosis of utmost importance. This work makes us pioneers in this field and may be an alternative in the weaponry of diagnostic tests for analyzing serum reactivity for cryptococcosis, independent of the antigenic charge of the fungus, currently used in tests like the lateral flow assay. Furthermore, after the identification of promising peptides for the use in immunoassay, opens up the prospect of its use in associations between the peptides, including peptides and proteins and even the development of new molecules as chimeric protein.

Studies with synthetic peptides to improve performance in the diagnosis of infectious diseases have shown promising results. Caldini *et al.* [18] showed a sensitivity of 100% and a specificity of 94.59% for the diagnosis of paracoccidioidomycosis using synthetic peptides. Other studies also showed good sensitivity (>88%) and specificity (>95%) in the diagnosis of infectious diseases [19–21,35].

In this work, we were able to successfully select some synthetic peptides that could contribute in an ELISA-based diagnostic test for cryptococcosis. In addition to the advantage of synthetic peptides being less expensive and fast to produce [19,36], our findings reveal peptides as promising candidate antigens for a diagnostic test for cryptococcosis.

Conclusion

In conclusion, using immunoproteomics and bioinformatics techniques, we were able to identify new antigenic promising targets for developing diagnostic tests for cryptococcosis. In this study, six synthetic peptides proved to be promising antigens in the immunodiagnosis of cryptococcosis. In addition, theoretical additive reactivities showed that the combination of peptides is an improved accuracy strategy for developing new antigenic targets.

Future perspective

Cryptococcosis is an important systemic mycosis that affects immunocompetent and immunosuppressed individuals. Cryptococcosis due to *C. gattii* has received much attention in

recent years due to outbreaks and the spread to countries not previously plagued by this pathogen. The early diagnosis of this infection is a challenge that science and health systems need to address because, in most cases, it is diagnosed late, resulting in significant mortality. Thus, efforts must be made in the search for a rapid, sensitive and specific diagnostic test. Our results have highlighted several peptides that can be used as antigens in immunoassays for the cryptococcosis diagnosis. The extension of this work in the field must be performed to confirm whether these peptides have an acceptable accuracy for the diagnosis of pulmonary cryptococcosis and/or the identification of subclinical infections in an endemic area for cryptococcosis.

Acknowledgements

The authors would like to thank João Batista de Oliveira Silva Júnior for translation of the manuscript into English and Fernando Ferraz do Nascimento for the statistical analyses. The authors also would like to thank the Renorbio Postgraduate Program for its incentive in the northeastern region of Brazil.

Financial & competing interests disclosure

This work was supported by the Laboratory of Immunogenetics and Molecular Biology, Federal University of Piauí, Brazil. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriateinstitutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

EXECUTIVE SUMMARY

Objectives of the study

- The objective was to identify new antigens for cryptococcosis immunodiagnostic tests.
- The study aimed to evaluate synthetic peptide performance against sera from subjects with cryptococcosis and other fungal infections.

Methods

- Synthesis of B-cell epitopes from *Cryptococcus gattii* immunoreactive proteins.
- Synthetic peptides were tested using ELISA to detect circulating antibodies in the serum of subjects with cryptococcosis.

Conclusion

- Synthetic peptides were found to be promising as new antigenic targets in cryptococcosis diagnosis.
- Six synthetic peptides had good performance with a high specificity and sensitivity in ELISA.

References

Papers of special note have been highlighted as:
• of interest; •• of considerable interest

1 Bovers M, Hagen F, Kuramae EE, Boekhout T. Six monophyletic lineages identified within *Cryptococcus neoformans* and *Cryptococcus gattii* by multi-locus sequence typing. *Fungal Genet. Biol.* 45(4), 400–421 (2008).

2 Warkentien T, Crum-Cianflone NF. An update on *Cryptococcus* among HIV-infected patients. *Int. J. STD AIDS* 21(10), 679–684 (2010).

3 Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS* 23(4), 525–530 (2009).

4 Kidd SE, Hagen F, Tscharke RL *et al.* A rare genotype of *Cryptococcus gattii* caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). *Proc. Natl Acad. Sci. USA* 101(49), 17258–17263 (2004).

5 Fraser JA, Giles SS, Wenink EC *et al.* Same-sex mating and the origin of the Vancouver Island *Cryptococcus gattii* outbreak. *Nature* 437(7063), 1360–1364 (2005).

6 Hagen F, Ceresini PC, Polacheck I *et al.* Ancient dispersal of the human pathogen *Cryptococcus gattii* from the Amazon rainforest. *PLoS ONE* 8(8), e71148 (2013).

7 Darze C, Lucena R, Gomes I, Melo A. The clinical laboratory characteristics of 104 cases of cryptococcal meningoencephalitis. *Rev. Soc. Bras. Med. Trop.* 33(1), 21–26 (2000).

8 Martins LM, Wanke B, Lazera Mdos S *et al.* Genotypes of *Cryptococcus neoformans* and *Cryptococcus gattii* as agents of endemic cryptococcosis in Teresina, Piaui (northeastern Brazil). *Mem. Inst. Oswaldo Cruz* 106(6), 725–730 (2011).

9 Nishikawa MM, Lazera MS, Barbosa GG *et al.* Serotyping of 467 *Cryptococcus neoformans* isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns. *J. Clin. Microbiol.* 41(1), 73–77 (2003).

10 Santos WR, Meyer W, Wanke B *et al.* Primary endemic *Cryptococcosis gattii* by molecular type VGII in the state of Para, Brazil. *Mem. Inst. Oswaldo Cruz* 103(8), 813–818 (2008).

11 Severo CB, Xavier MO, Gazzoni AF, Severo LC. Cryptococcosis in children. *Paediatr. Respir. Rev.* 10(4), 166–171 (2009).

12 Hansen J, Slechta ES, Gates-Hollingsworth MA *et al.* Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. *Clin. Vaccine Immunol.* 20(1), 52–55 (2013).

13 Lindsley MD, Mekha N, Baggett HC *et al.* Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. *Clin Infect. Dis.* 53(4), 321–325 (2011).

14 McMullan BJ, Halliday C, Sorrell TC *et al.* Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. *PLoS ONE* 7(11), e49541 (2012).

15 Dhana A. Diagnosis of cryptococcosis and prevention of cryptococcal meningitis using a novel point-of-care lateral flow assay. *Case Rep. Med.* 2013, 1–4 (2013).

16 Rugemalila J, Maro VP, Kapanda G *et al.* Cryptococcal antingen prevalende in JIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. *Trop. Med. Int. Health* 18(9), 1075–1079, 2013.

17 Martins LM, De Andrade HM, Vainstein MH *et al.* Immunoproteomics and immunoinformatics analysis of *Cryptococcus gattii*: novel candidate antigens for diagnosis. *Future Microbiol.* 8(4), 549–563 (2013).

•• **Peptides identification as potential antigens to cryptococcosis diagnosis.**

18 Caldini CP, Xander P, Kioshima ES *et al.* Synthetic peptides mimic gp75 from *Paracoccidioides brasiliensis* in the diagnosis of paracoccidioidomycosis. *Mycopathologia* 174(1), 1–10 (2012).

•• **Synthetic peptides as antigens to paracoccidioidomycosis diagnosis.**

19 Faria AR, Costa MM, Giusta MS *et al.* High-throughput analysis of synthetic peptides for the immunodiagnosis of canine visceral leishmaniasis. *PLoS Negl. Trop. Dis.* 5(9), e1310 (2011).

•• **Synthetic peptides as antigens for the immunodiagnosis of leishmaniasis.**

20 Bottino CG, Gomes LP, Pereira JB, Coura JR, Provance DW Jr, De-Simone SG. Chagas disease-specific antigens: characterization of epitopes in CRA/FRA by synthetic peptide mapping and evaluation by ELISA-peptide assay. *BMC Infect. Dis.* 13, 568 (2013).

21 Shen G, Behera D, Bhalla M, Nadas A, Laal S. Peptide-based antibody detection for tuberculosis diagnosis. *Clin. Vaccine Immunol.* 16(1), 49–54 (2009).

22 Araujo Z, Giampietro F, Bochichio Mde L *et al.* Immunologic evaluation and validation of methods using synthetic peptides derived from *Mycobacterium tuberculosis* for the diagnosis of tuberculosis infection. *Mem. Inst. Oswaldo Cruz* 108(2), 131–139 (2013).

23 Gori A, Longhi R, Peri C, Colombo G. Peptides for immunological purposes: design, strategies and applications. *Amino Acids* 45(2), 257–268 (2013).

24 Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. *Prev. Vet. Med.* 45(1–2), 23–41 (2000).

25 Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. *Am. J. Epidemiol.* 163(7), 670–675 (2006).

26 Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. *Epidemiology* 16(1), 73–81 (2005).

27 Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. *Cell Mol. Life Sci.* 62(6), 670–684 (2005).

28 Kakeya H, Udono H, Ikuno N *et al.* A 77-kilodalton protein of *Cryptococcus neoformans*, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. *Infect. Immun.* 65(5), 1653–1658 (1997).

29 Kakeya H, Udono H, Maesaki S *et al.* Heat shock protein 70 (hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. *Clin. Exp. Immunol.* 115(3), 485–490 (1999).

30 Rodrigues ML, Nakayasu ES, Oliveira DL *et al.* Extracellular vesicles produced by *Cryptococcus neoformans* contain protein components associated with virulence. *Eukaryot. Cell* 7(1), 58–67 (2008).

• **Proteins involved in the cryptococcosis virulence.**

31 Silveira CP, Piffer AC, Kmetzsch L *et al.* The heat shock protein (Hsp) 70 of *Cryptococcus neoformans* is associated with the fungal cell surface and influences the interaction between yeast and host cells. *Fungal Genet. Biol.* 60, 53–63 (2013).

• **Hsp70 importance in the cryptococcosis pathogenesis.**

32 Houghton RL, Lodes MJ, Dillon DC *et al.* Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. *Clin. Diagn. Lab. Immunol.* 9(4), 883–891 (2002).

33 Khan IH, Ravindran R, Yee J *et al.* Profiling antibodies to *Mycobacterium tuberculosis* by multiplex microbead suspension arrays for serodiagnosis of tuberculosis. *Clin. Vaccine Immunol.* 15(3), 433–438 (2008).

34 Chavez-Fumagalli MA, Martins VT, Testasicca MC *et al.* Sensitive and specific serodiagnosis of *Leishmania infantum* infection in dogs by using peptides selected from hypothetical proteins identified by an immunoproteomic approach. *Clin. Vaccine Immunol.* 20(6), 835–841 (2013).

• **Synthetic peptides from hypothetical proteins used for the serodiagnosis of leishmaniasis.**

35 Peralta JM, Teixeira MG, Shreffler WG *et al.* Serodiagnosis of Chagas' disease by enzyme-linked immunosorbent assay using two synthetic peptides as antigens. *J. Clin. Microbiol.* 32(4), 971–974 (1994).

36 Malakoutikhah M, Gomara MJ, Gomez-Puerta JA, Sanmarti R, Haro I. The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis. *J. Med. Chem.* 54(21), 7486–7492 (2011).

37 PEPTIDE 2.0 Inc. www.peptide2.com

Table S2. Synthetic peptides derived from immunoreactive proteins of Cryptococcus gattii and the amino acid sequences used as antigen in the serodiagnosis of cryptococcosis.

Peptide name	Proteins	Amino Acid sequence
S1	Heat Shock Protein sks2	EGAIGIDLGTTYSC
S2	Heat Shock Protein sks2	TTPSYVAFTEGERL
S3	Heat Shock Protein sks2	RRYDDADVKKDMKH
S4	Heat Shock Protein sks2	VIDKDGSPYVEVDY
S5	Heat Shock Protein sks2	NEKKTFSPQEISAM
S6	Heat Shock Protein sks2	EVLRIINEPTAAAI
S7	Heat Shock Protein sks2	IFDLGGGTFDVSLL
S8	Heat Shock Protein sks2	GDTHLGGEDFDNNL
S9	Heat Shock Protein sks2	HFKAEFKRKTKLDI
S10	Heat Shock Protein sks2	TAFKSTVDPVDKVL
S11	Heat Shock Protein sks2	SINPDEAVAYGAAV
S12	Heat Shock Protein sks2	VLPRNTPIPSNKSR
S13	Heat Shock Protein sks2	PVYEGERTQCKDNR
S14	Heat Shock Protein sks2	GIPPMPRGQAELVC
S15	Heat Shock Protein sks2	DRASGRKAQITIQN
H16	Heat Shock Protein (Hsp70)	PAKTAETSNFKNTI
H17	Heat Shock Protein (Hsp70)	RSVNDPEVEEFEKK
H18	Heat Shock Protein (Hsp70)	VDVNGEIGVKVNYL
H19	Heat Shock Protein (Hsp70)	VLCSTPPTLPGLNA
H20	Heat Shock Protein (Hsp70)	GHSDYSVAVVAFSK
H21	Heat Shock Protein (Hsp70)	RHFGGRDFDYALVQ
H22	Heat Shock Protein (Hsp70)	FRLTTGCERLKKVL
H23	Heat Shock Protein (Hsp70)	QDEAIARGATFACA
H24	Heat Shock Protein (Hsp70)	KEAGNPDEDTELVV
H25	Heat Shock Protein (Hsp70)	TANPIPSTKVLTFY
H26	Heat Shock Protein (Hsp70)	EASYADPATLPKGI

H27	Heat Shock Protein (Hsp70)	EEEVTVGEGEDAKT
H28	Heat Shock Protein (Hsp70)	KKIQRKGDCPVVGQ
H29	Heat Shock Protein (Hsp70)	KEALLQGLQEAEDW
H30	Heat Shock Protein (Hsp70)	EEGEDASKSAYVQK
H31	Heat Shock Protein (Hsp70)	RWKESEERPKAAAA
H32	Heat Shock Protein (Hsp70)	TYLTAAQGEDEKYS
G33	GrpE Protein	MNPRSLTTAVRSFT
G34	GrpE Protein	AARTFTPQLQARAY
G35	GrpE Protein	RADVQTAVRRSAEE
G36	GrpE Protein	TALKHVPQPIPAEN
G37	GrpE Protein	LKTFESHGVKKLEN
G38	GrpE Protein	AVAPKKDNGEPHGP
E39	Phosphopyruvate hydratase (enolase)	TEKGLFRAEVPSGA
E40	Phosphopyruvate hydratase (enolase)	AVELRDKGSDYMGK
E41	Phosphopyruvate hydratase (enolase)	AANVGDEGGFAPNV
E42	Phosphopyruvate hydratase (enolase)	SEFFKDGKYDLDFK
E43	Phosphopyruvate hydratase (enolase)	SIEDPFHEDDFDAW
E44	Phosphopyruvate hydratase (enolase)	SHRSGETESTYIAD
Hy45	conserved hypothetical protein CGNB 1302	AKHAVPHSHEKADI
Hy46	conserved hypothetical protein CGNB 1302	EHAPKVTPGKENVQ
Hy47	conserved hypothetical protein CGNB 1302	DRAVASDDPKDVNP
Hy48	conserved hypothetical protein CGNB 1302	SKKEGKGDKAGEDQ

Hy49	conserved hypothetical protein CGNB 1302	PEAKSGGASANETA
Hy50	conserved hypothetical protein CGNB 1302	QKSANANKGEEKTE
Hy51	conserved hypothetical protein CGNB 1302	KQQGSEEGAPSAQD
Hy52	conserved hypothetical protein CGNB 1302	VTHVMVVGHTGCGG
X53	conserved hypothetical protein CGNB 1079	LKKMATEQLENALN
X54	conserved hypothetical protein CGNB 1079	GNNNYSSGNNTQGS
X55	conserved hypothetical protein CGNB 1079	SQQRYGGNQNQSYG
X56	conserved hypothetical protein CGNB 1079	SQNQGYGQQPGGYG
X57	conserved hypothetical protein CGNB 1079	GGYGQQENYGGQNQ
X58	conserved hypothetical protein CGNB 1079	GGAQYNRPHGQGGA
X59	conserved hypothetical protein CGNB 1079	AANEHNSNGNENSS
X60	conserved hypothetical protein CGNB 1079	LSFIGNMNKNDTDI
X61	conserved hypothetical protein CGNB 1079	AYGQGNTSGMTSSS
X62	conserved hypothetical protein CGNB 1079	AADTSGNKQGGGDM
X63	conserved hypothetical protein CGNB 1079	FDSSGGNIQGNKQD

Research Article
Future Microbiology

Immunoproteomics and immunoinformatics analysis of *Cryptococcus gattii*: novel candidate antigens for diagnosis

Liline Maria Soares Martins*[1,2], Hélida Monteiro de Andrade[3], Marilene Henning Vainstein[4], Bodo Wanke[5], Augusto Schrank[4], Claudia Bemfica Balaguez[4], Patrícia Ribeiro dos Santos[4], Lucélia Santi[4], Simone da Fonseca Pires[3], Adalberto Socorro da Silva[1], José Adail Fonseca de Castro[1,2], Rafael Melo Santos de Serpa Brandão[1] & Semiramis Jamil Hadad do Monte[1]

[1]Laboratório de Imunogenética e Biologia Molecular, Universidade Federal do Piauí, Campus Ministro Petrônio Portella Bloco SG-16, 64049-550, Teresina, Piauí, Brazil
[2]Faculdade de Ciências Médicas da Universidade Estadual do Piauí, Teresina, Piauí, Brazil
[3]Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Parasitologia, Belo Horizonte, Minas Gerais, Brazil
[4]Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
[5]Laboratório de Micologia, Instituto de Pesquisa Clínica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil
*Author for correspondence: liline-martins@uol.com.br

Aim: To identify immunoreactive proteins of *Cryptococcus gattii* genotype VGII and their B-cell epitopes. **Materials & methods:** We combined 2D gel electrophoresis, immunoblotting and mass spectrometry to identify immunoreactive proteins from four strains of *C. gattii* genotype VGII (CG01, CG02, CG03 and R265). Next, we screened the identified proteins to map B-cell epitopes. **Results:** Sixty-eight immunoreactive proteins were identified. The strains and the number of proteins we found were: CG01 (12), CG02 (12), CG03 (18) and R265 (26). In addition, we mapped 374 peptides potentially targeted by B cells. **Conclusion:** Both immunoreactive proteins and B-cell epitopes of *C. gattii* genotype VGII that were potentially targeted by a host humoral response were identified. Considering the evolutionary relevance of the identified proteins, we may speculate that they could be used as the initial targets for recombinant protein and peptide synthesis aimed at the development of immunodiagnostic tools for cryptococcosis.

Cryptococcosis has become a significant public global health problem. The CDC estimate the occurrence of over 1 million new cases per year of cryptococcosis worldwide in patients with AIDS and, despite the recent improvements in the diagnosis and treatment of cryptococcosis, cryptococcal meningitis is responsible for over 600,000 deaths per year worldwide. This potentially fatal fungal disease is caused by one of two species of the same genus: *Cryptococcus neoformans* (genotypes VNI–VNIV) or *Cryptococcus gattii* (genotypes VGI–VGIV). The first species is best known as the cause of severe meningoencephalitis or meningitis in immunocompromised patients and has been considered to be the most medically important species for many years [1–5]. It is important for clinical microbiology laboratories to accurately differentiate one species from the other. Rapid identification of *C. neoformans* and *C. gattii* is imperative for favoring the prompt treatment of cryptococcosis and for understanding the epidemiology of the disease [6–11]. *C. gattii* merits more attention so that its environmental occurrence and role in cryptococcosis can be accurately determined, as this information will be helpful in devising strategies to manage potential outbreaks of cryptococcosis. Today, the differentiation between *C. neoformans* and *C. gattii* is a difficult task since: the available commercial differentiation methods (e.g., API® 20C AUX [bioMérieux, France], Vitek® [bioMérieux] and MicroScan® [Siemens, Germany]) do not differentiate between *C. neoformans* and *C. gattii*; and the methods capable of differentiating the two species (multiplex PCR, liquid array detection of pathogens, PCR restriction fragment length polymorphism [12,13] and matrix-assisted laser desorption/ionization mass spectrometry [MS] [14–16]) are not routinely used.

Recently, however, increased medical attention has been paid to *C. gattii*, which mainly affects immunocompetent individuals [1,2,17]. The interest in clinical studies of this species has arisen due to its rapid spread in Asia, Africa, Australia, Europe and South America, along with outbreaks in Vancouver Island, BC, Canada, and in parts

Keywords
■ B cell ■ cryptococcosis ■ *Cryptococcus gattii* ■ diagnosis ■ epitopes ■ immunoinformatics ■ immunoproteomics

Future Medicine part of fsg

of continental North America. The potential for *C. gattii* to cause illness in immunocompetent patients and its rapid spread worldwide justify the implementation of a public health effort to increase the awareness of both the public and healthcare professionals [1,18–24]. The mechanism of *C. gattii* dispersion is not well understood. However, it is thought that the emergence of industrialization, as well as the subsequent development of high population densities, concurrent with processes such as the export of trees and wood products, transport of bacteria via air currents, water currents and biotic agents (e.g., birds, animals and insects) and global warming, may be the main catalysts for the spread of this pathogen [1,2]. As cryptococcosis does not require compulsory notification in Brazil, and there is currently no surveillance of this mycosis, its prevalence and annual incidence can only be approximately estimated based on publications of cases occurring in specialized services. Nevertheless, it is well known that the clinical cases attributed to these two species of the *Cryptococcus* genus are distributed differently throughout Brazil, with *C. neoformans* being predominant in the south and southeast and *C. gattii* (mainly genotype VGII) being predominant in the north and northeast regions. In these latter two regions, *C. gattii* affects immunocompetent adults, adolescents and children, and is associated with high morbidity and mortality rates (ranging from 37 to 49%). Information regarding the conditions that support the development of cryptococcosis in immunocompetent individuals remains elusive. However, it is possible that environmental factors play an important role in this process, considering that people living in endemic areas are at high risk for developing the disease [21,25–30]. Preventative measures that effectively combat infection by *C. gattii* are not available at present. Hence, the best approach for controlling cryptococcosis is through early diagnosis and treatment. Although recent advances directed at early diagnosis of cryptococcosis have been published [31–33], a diagnostic method with high specificity and sensitivity to guide the management and control of cryptococcosis remains to be developed.

Information from the recently published *C. gattii* genome, combined with data obtained via proteomic approaches, has created opportunities for the development of diagnostic tools and therapeutic targets in the context of cryptococcosis caused by *C. gattii* [18]. The development of such tools has been improved by the production of antigens, which increases the range of alternative tests for immunoassay-based pathogen detection. In this study, we identify both immunoreactive proteins of *C. gattii* and predicted B-cell epitopes for their potential use as antigens in new serologic tests.

Materials & methods

Study patients & sera

The study included three immunocompetent subjects with cryptococcal meningitis recruited at the Natan Portella Institute of Tropical Diseases, a reference center for infectious diseases in Teresina, the capital of the northeastern state of Piauí, Brazil. As negative controls, we used sample sera from uninfected subjects (n = 3) who did not present clinical indicators or positive serological tests for cryptococcosis. The sera obtained from these patients were stored in a freezer at -20°C until use. The demographic, epidemiological, laboratory and baseline clinical characteristics of each patient were obtained from medical records and transferred to an epidemiological sheet. Detailed information regarding the patients involved in this study was published by Martins *et al.* [26]. Sera from three immunocompetent patients with cryptococcal meningitis caused by *C. gattii* genotype VGII were selected to produce a pool of serum containing each antigen at a titer of 1:1024 as determined by the latex agglutination test for diagnosing cryptococcosis. This pooled serum was used for all western blot experiments.

C. gattii strains

C. gattii proteins were screened in four different strains. The first strain, R265 (ATCC number: MYA 4093), was previously identified by Kidd *et al.* [20] and was kindly provided by MH Vainstein from the culture collection of the Laboratory of Fungi of Medical and Biotechnological Importance from the Biotechnology Center, Federal University of Rio Grande do Sul (UFRGS), Brazil. The other three *C. gattii* strains (CG01, CG02 and CG03) molecular type/genotype VGII involved in this study were isolated from immunocompetent patients who had cryptococcal meningitis (two children and one adult, from the state of Piauí, northeastern Brazil). These isolates were submitted to strain identification [26], which was performed via PCR restriction fragment length polymorphism analysis using *URA5* as a target gene, as described by Meyer *et al.* [34].

Culture conditions

Strains were recovered from 15% skimmed milk stocks, stored at -20°C prior to use. The strains

were maintained on yeast extract–peptone–dextrose (YPD) media (1% yeast extract, 2% peptone, 2% dextrose and 2% Bacto™ Agar, Becton Dickinson, NJ, USA). Each isolate was inoculated and grown in 200 ml of YPD broth at 37°C for 24 h with shaking at 200 rpm. To obtain a better protein yield, the cultures were subsequently quantified in a Neubauer chamber, reseeded to an equivalent of 4×10^7 cells/ml in 200 ml YPD final broth and incubated under the same conditions as described above. After 24 h, the cells were collected via centrifugation at 7500 *g* for 10 min at 10°C and washed three times in cold, sterile Milli-Q® water (Millipore Corp., MA, USA). The cell pellet obtained was stored at -80°C.

Preparation of protein extracts

Prior to the extraction process, the samples were lyophilized (FreeZone® lyophilizer, Labconco, MI, USA) and macerated in liquid nitrogen until a fine powder was obtained. The samples were suspended in a lysis buffer with protease inhibitors and detergents (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride, 50 µM N-*p*-tosyl-L-phenylalanine chloromethyl ketone, 5 mM iodoacetamide, 4% w/v 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS) and 0.25% v/v Triton™ X-100). The proteins were solubilized by vortexing the suspensions for 5 min at intervals of 1 min on ice, followed by centrifugation at 10,000 *g* for 20 min at 8°C. The supernatants were collected and preserved at -20°C. The remaining cell debris was suspended in the same buffer, followed by vortexing for 5 min with intervals on ice every 1 min. The supernatant was collected after centrifugation, pooled with the first supernatant and stored at -80°C. The protein content was determined by the Bradford method [35] using known concentrations of bovine serum albumin as the standard.

2D gel electrophoresis

Samples containing 150 µg of protein were precipitated using a 2D gel electrophoresis (2DE) clean-up kit (GE Healthcare, UK) following the manufacturer's instructions, then solubilized in 150 µl of isoelectric focusing (IEF) buffer containing 9 M urea, 4% (w/v) CHAPS, 1% (w/v) dithiothreitol (DTT) and 0.2% (v/v) ampholytes pH 4–7 (Bio-Rad, CA, USA) with 0.002% orange G. Next, 7-cm immobilized pH gradient (IPG) strips (linear gradient, pH 4–7, Bio-Rad) were passively rehydrated for 16–18 h. IEF was performed using the PROTEAN® IEF Cell System (Bio-Rad) at 20°C with the following conditions: 250 V for 15 min, 250–4000 V for 2 h and 4000 V until reaching 10,000 V/h, with a maximum current of 50 µA/strip. Focused IPG strips were equilibrated for 15 min in equilibration buffer I, containing 30% (v/v) glycerol, 6 M urea, 1% DTT, 2% (w/v) sodium dodecyl sulfate (SDS), 0.375 M Tris pH 8.8 and 0.002% Bromophenol Blue, and then alkylated for 15 min in equilibration buffer II (equilibration buffer I in which the DTT was replaced with 4% iodoacetamide). SDS-PAGE was performed using the method developed by Laemmli [36]. The IPG strips were then placed on a 12% SDS-PAGE gel, and the second dimension of separation was performed in two steps at 10°C: 50 V/gel for 30 min and 100 V/gel until the tracking dye reached the bottom of the gels in a Mini-PROTEAN Tetra Cell Chamber (Bio-Rad), according to the manufacturer's instructions. The gels were stained with Coomassie Brilliant Blue and scanned with a GS-800™ scanner (Bio-Rad). Three technical replicates of classical 2DE western blots for each of the four independent biological samples were performed for each strain. A Coomassie Brilliant Blue G250 gel and the other duplicate gel were transferred onto a polyvinylidene difluoride membrane for subsequent western blot analysis [37].

Western blot: 2DE analysis

The gels were transferred to polyvinylidene difluoride membranes (Hybond ECL™, GE Healthcare) at 400 mA for 1 h in a transfer buffer (25 mM Tris, 192 mM glycine, 2% w/v SDS and 20% v/v methanol). The membranes were blocked at 4°C overnight with 5% (w/v) nonfat dry milk in phosphate-buffered saline pH 7.4 with Tween®-20 (PBS-T; 10 mM Na_2HPO_4, 1.7 mM KH_2PO_4, 137 mM NaCl, 2.7 mM KCl, and 0.1% v/v Tween-20, Sigma Aldrich, MO, USA) and washed three times for 10 min. The membranes were then incubated with pools of sera from three patients with cryptococcal meningitis, diluted 1:7500 in blocking buffer for 2 h at 24°C. This primary antibody dilution was previously determined based on performing western blotting using a 1D gel with serum dilutions ranging from 1:2000 to 1:10,000. After washing three times with PBS-T, the blots were incubated with antihuman IgG (GE Healthcare) diluted 1:2000 in blocking buffer for 1 h at 24°C. The membranes were washed three times with PBS-T buffer for 15 min and twice with phosphate-buffered saline for 10 min. Finally, the 2DE blots were processed with the ECL detection

reagent (GE Healthcare) according to the manufacturer's instructions. Images were prepared using the VersaDoc™ 4000 MP imaging system (Bio-Rad). The western blots were evaluated in technical triplicates. The immunoreactivity of each spot, representing a positive signal in the western blot analysis, was identified by matching with the position of the corresponding spot on the gel stained with Coomassie Brilliant Blue. To select spots, the images from membranes and gels containing protein extracts were analyzed using an ImageMaster 2D Platinum 6.0® (GE Healthcare). In order to identify any nonspecific reactions, we discarded all spots that were also reactive with the pool of sera from negative controls. Only the infected reactive spots sera were manually excised, destained, digested with trypsin and subjected to MS to identify the immunoreactive proteins.

Protein identification by liquid chromatography-electrospray ionization-quadrupole-time of flight tandem MS

Gel plugs were treated through three washing steps with 100 µl of 50% acetonitrile (ACN) and 50 mM ammonium bicarbonate (NH_4HCO_3) for 15 min, followed by one washing step with 100 µl of ACN. After washing, the gel plugs were dried via vacuum centrifugation (CentriVap® Benchtop Centrifugal Vacuum concentrator, Labconco) and subjected to trypsin digestion for 18–24 h at 37°C using 20 µl of 10 µg/ml trypsin (Trypsin Gold, MS grade, Promega, WI, USA) diluted in 25 mM NH_4HCO_3. Peptide extraction was performed twice for 15 min with 100 µl of a 100% ACN and 5% formic acid solution. Trypsin digests were then concentrated in a SpeedVac® concentrator to approximately 10 µl and resuspended in 10 µl of 0.1% trifluoroacetic acid.

The resulting peptides were analyzed by liquid chromatography-electrospray ionization-quadrupole-time of flight tandem mass spectrometry (MS/MS) using a Waters nanoACQUITY UPLC™ system coupled to a Q-TOF Ultima™ API mass spectrometer (Waters MS Technologies, UK) at the Unit of Protein Chemistry and Mass Spectrometry (Uniprote-MS, Biotechnology Center, UFRGS, Brazil). The peptides were eluted from the reverse-phase column into the mass spectrometer at a flow rate of 600 nl/min with a 10–50% water/ACN 0.1% formic acid linear gradient over 30 min. The MS survey scan was set to 1 s (0.1 s interscan delay) and recorded at 200–2000 Da. MS/MS scans were performed from 50 to 2000 m/z, and the scan and interscan rates were set as for MS. For each survey scan, the three most intense multiple-charged ions over a threshold of eight counts were selected for the MS/MS analysis. The collision energies for peptide fragmentation were set using the charge state recognition files for +2 and +3 peptide ions provided by MassLynx™ (Waters). The raw MS/MS data were processed using Mascot Distiller 2.2.1 software (Matrix Science, MA, USA) to form peak lists that were exported in the Mascot generic format.

Database searches

The peak lists for each protein spot were analyzed with the aid of the 'MS/MS Ion Search' engine of Mascot (version 2.1) software [101]. The Mascot search parameters were as follows: oxidation of methionine, modification of cysteine by carbamidomethylation, partial cleavage leaving one internal cleavage site, a peptide tolerance of 0.2 Da and a MS/MS tolerance of 0.1 Da. The significance threshold was set at $p < 0.05$, and identification required that each protein contained at least one peptide with an expected p-value < 0.05. Thus, we compared the calculated molecular mass and isoelectric point values from the identified proteins with the observed values on the 2DE gel. Additionally, if a protein with a nonsignificant score was part of a horizontal series of spots with the adjacent identical proteins, we included this identification. All amino acid sequences were downloaded as FASTA-format files from the Broad Institute protein database [102]. The Blast2GO tool [103] was used to obtain functional categories of proteins. This tool assigns gene ontology (GO) terms based on the Basic Local Alignment Search Tool (BLAST) definitions. This assignment was accomplished by submitting the FASTA sequences of the identified proteins to the Blast2GO platform and comparing them against the National Center for Biotechnology Information (NCBI) databases [104]. Briefly, Blast2GO used BlastP with the default parameters to identify similar proteins with GO annotations.

Mapping B-cell epitopes

To map linear B-cell epitopes in the immunoreactive proteins selected by western blotting, we used two different programs: ABCPred [105], which is based on machine-learning methods that apply a recurrent neural network [38], and BCPreds [106], which is also based on machine-learning methods, but involves methods that apply a support vector machine [39]. Only those

peptides that were simultaneously identified by the two programs were considered to be putative antigens for the development of immunoassays for cryptococcosis. This approach was based on the work of Faria *et al.*, which showed that the use of the default scores of prediction software programs associated with the overlap predictions of more than one software program can be preferable to the use of a single type of prediction [40].

Results

2DE proteome profiling of *C. gattii* strains

Proteins from *C. gattii* strain R265 and our isolates (CG01, CG02 and CG03) were separated using 2DE and analyzed for reactivity to the serum by immunoblotting. In fact, the capsule was a major obstacle to obtaining protein. The key points to improve protein recovery were background culture in liquid medium and lyophilization with maceration in liquid nitrogen. After these steps, proteins were obtained by solubilization in a lysis buffer containing 4% detergent (CHAPS). Protein samples obtained in this manner are mainly cytoplasmatic proteins and a trace quantity of membrane proteins associated to carbohydrates.

A representative image of the protein patterns is shown in Figure 1. Image analysis demonstrated approximately 350 spots for each strain of *C. gattii* (Figure 1), all of which optimally resolved at pH 4–7, and their molecular weights ranged from 12 to 225 kDa.

Only 68 of these spots showed reactivity based on immunoblotting against a pool of sera from cryptococcosis patients. One hypothesis to explain the low number of proteins identified by immunoblotting is that most of the proteins were cytoplasmic, together with the fact that many surface antigens of this fungus are located in capsules and should be represented mainly by carbohydrates.

The distribution of the spots for each strain is as follows: 12 spots from CG01; 12 from CG02; 18 from CG03; and 26 from R265. All of the immunoreactive spots selected for identification with MS were classified according to their biological activity (Table 1 & Supplementary Table 1) (see online at: www.futuremedicine.com/doi/suppl/10.2217/FMB.13.22). The data generated by the Blast2GO analysis are presented at GO multilevels to illustrate the general functional categories according to biological processes and molecular functions (Supplementary Figures 1 & 2) [103]. Of the 68 spots corresponding to 48 proteins, 34 (70.8%) were selected from only one strain, and 14 (29.2%) were simultaneously derived from at least two strains; among the latter 14 proteins, six were simultaneously selected from three strains (Figure 2).

Prediction of B-cell linear epitopes

We sought to determine whether the 48 reactive proteins identified in this study shared epitopes that were potentially recognized by patient antibodies. Therefore, we screened these proteins for predictive B-cell epitopes using two different bioinformatics tools. The ABCPred program yielded 4747 peptides, whereas BCPreds yielded 475. By comparing the B-cell epitopes generated by these two different approaches, we were able to identify 374 concordant peptides (the peptide sizes ranged from nine to 14 amino acids) (Supplementary Table 2). We believe that the B-cell prediction was efficient because the majority of the proteins (41/48; 85.4%) presented in a high percentage (greater than 25%) of the epitopes (Table 2). This percentage of epitopes takes into account the total number of predicted peptides and the total number of amino acids in the mapped protein. Two hypothetical proteins (CNBG_1302 and CNBG_1079) contained the highest number of predicted peptides. Proteins and peptides with a greater potential of being B-cell epitopes deserve further investigation as candidate antigens for use in diagnostic testing.

Discussion

In this immunoproteomic study, we identified immunoreactive proteins in *C. gattii*, as well as the putative B-cell epitopes of these predicted proteins using immunoinformatics tools. The proteins recognized *in vitro* by antibodies in this work probably have the same antigenic determinants that induce antibodies *in vivo*. This approach has frequently been used to identify immunogenic proteins and, consequently, new targets to diagnose several diseases [41–54]. Although similar results have been achieved in cryptococcosis using murine [55] and koala models [56], this is the first report in human beings. In addition, the use of sample isolates obtained directly from patients would be very difficult, because they are hard to obtain directly from the brain or lung during infection, and the sample collected would probably not have a sufficient amount of protein for a proteomic approach.

We identified 68 immunoreactive proteins and highlight that only six of them were reactive in three isolates simultaneously without a reaction for negative sera. Due to their



Figure 1. Western immunoblot analysis of representative serum samples. *Cryptococcus gatti* proteins in 2D gel electrophoresis: **(A)** CGOI, **(B)** CGO2, **(C)** CGO3 and **(D)** R265. Representative results of immunoblot from the pool of patient sera with cryptococcosis: **(E)** CGO1, **(F)** CGO2, **(G)** CGO3 and **(H)** R265 strains. **(I)** Result of immunoblot from the sera of uninfected person with cryptococcosis. The numbers refer to the spot identification used in Table 1.
MW: Molecular weight.

Table 1. Immunodominant proteins identified by serologic proteome analysis.

Spot/strain	Protein	Accession code	Mascot ID	Biological process	Molecular function
11A/CG01	Microtubule motor	E6R0Y5	CNBG_0115	Microtubule-based movement	ATP binding; microtubule motor activity
25D/R265	Heat shock protein sks2	E6R0K8	CNBG_0239	Response to stress	ATP binding
21D/R265	HHE domain-containing protein	E6R0I8	CNBG_0257	Unknown	Unknown
11C/CG03	Cytoplasm protein	E6R0G3	CNBG_0282	Unknown	Binding
5A/CG01	Conserved hypothetical protein	E6R0C0	CNBG_0290	Unknown	Unknown
7C/CG03	Conserved hypothetical protein	E6R068	CNBG_0372	Unknown	RNA binding
3D/R265	Ubiquitin carboxyl-terminal hydrolase	E6R058	CNBG_0379	Ubiquitin-dependent protein catabolic process	Ubiquitin thiolesterase activity
17D/R265	Disulfide-isomerase	E6QZV4	CNBG_0482	Cell redox homeostasis	Electron carrier activity; isomerase activity; protein disulfide oxidoreductase activity
9B/CG02	Conserved hypothetical protein	E6R3U6	CNBG_0624	Unknown	Unknown
12B/CG02	Aconitase	E6R432	CNBG_0705	Tricarboxylic acid cycle	Four-iron, four-sulfur cluster binding; aconitate hydratase activity
22D/R265	Cytoplasm protein	E6R4T7	CNBG_0959	Unknown	Unknown
8D/R265	Conserved hypothetical protein	E6R568	CNBG_1079	Unknown	Unknown
6B/CG02	Succinyl-CoA ligase β-chain	E6QYK0	CNBG_1185	Tricarboxylic acid cycle	ATP binding; succinate-CoA ligase (ADP-forming) activity
9C/CG03	Succinyl-CoA ligase β-chain	E6QYK0	CNBG_1185	Reductive tricarboxylic acid cycle	ATP binding
18D/R265	Succinyl-CoA ligase β-chain	E6QYK0	CNBG_1185	Tricarboxylic acid cycle	ATP binding
12C/CG03	Conserved hypothetical protein	E6QY79	CNBG_1302	Unknown	Unknown
3B/CG02	Endopeptidase	E6QY25	CNBG_1355	Proteolysis	Aspartic-type endopeptidase activity
8C/CG03	3-isopropylmalate dehydrogenase	E6QXQ4	CNBG_1460	Oxidation reduction	NAD or NADH binding
16D/R265	3-isopropylmalate dehydrogenase	E6QXQ4	CNBG_1460	Oxidation reduction	3-isopropylmalate dehydrogenase activity; NAD binding
4B/CG02	ATP synthase β-subunit	E6R8N5	CNBG_1632	ATP hydrolysis-coupled proton transport	ATP binding; hydrogen ion-transporting ATP synthase activity
15D/R265	ATP synthase β-subunit	E6R8N5	CNBG_1632	ATP catabolic process	Proton-transporting ATPase activity, rotational mechanism
6D/R265	Ketol-acid reductoisomerase	E6R847	CNBG_1816	Oxidation reduction	Coenzyme binding; isomerase activity; ketol-acid reductoisomerase activity
1C/CG03	Glyceraldehyde-3-phosphate dehydrogenase	E6R7Z5	CNBG_1866	Glycolysis	NAD binding; glyceraldehyde-3-phosphate dehydrogenase (NAD^+) phosphorylating activity
1B/CG02	Mannitol-1-phosphate dehydrogenase	E6RA07	CNBG_2079	Oxidation reduction	Oxidoreductase activity; zinc ion binding

The data are sorted by Mascot ID in crescent order.



Figure 2. Venn diagram showing immunodominant proteins identified by serologic proteome from four *Cryptococcus gattii* strains. Strains, spots and protein names are according to Table 1.

Table 2. Proteins and B-cell epitopes mapped by ABCPred and BCPreds algorithms identified by immunoblot sera from patients with cryptococcosis.

Protein ID (aa†)	Accession code	Name of protein	WB strain‡	Epitopes (n)	Epitopes (%)§
CNBG_1302§ (222)	E6QY79	Conserved hypothetical protein	CG03	9	47
CNBG_1079§ (302)	E6R568	Conserved hypothetical protein	R265	11	42
CNBG_3163 (225)	E6RDR5	Wos2 protein	CG02	8	41
CNBG_0115 (595)	E6R0Y5	Microtubule motor	CG01	21	40
CNBG_2923 (292)	E6RBG9	40S ribosomal protein S0	CG01, CG03, R265	9	35
CNBG_0705 (780)	E6R432	Aconitase	CG02	23	34
CNBG_0282 (334)	E6R0G3	Cytoplasm protein	CG03	10	34
CNBG_4548 (239)	E6R5R6	CAN2 protein	CG03	7	34
CNBG_4834 (459)	E6RF86	Translation elongation factor EF1-α	R265	13	33
CNBG_4027 (281)	E6R6Y7	Ubiquinol–cytochrome-C reductase iron–sulfur subunit	CG01, CG03	8	33
CNBG_3631 (138)	E6R286	Cofilin	CG03	4	33
CNBG_5365 (431)	E6R762	Cellulase	CG02	12	32
CNBG_5509 (213)	E6QZ83	Conserved hypothetical protein	R265	6	32
CNBG_3378 (216)	E6R3K5	Elongation factor 1β	CG01, CG03, R265	5	32
CNBG_1866 (336)	E6R7Z5	Glyceraldehyde-3-phosphate dehydrogenase	CG03	9	31
CNBG_4560 (225)	E6R5Q4	Conserved hypothetical protein	R265	6	31
CNBG_6164 (187)	E6RED0	Conserved hypothetical protein	CG01, CG03	5	31
CNBG_3060 (228)	E6RDF4	GrpE protein	CG01, CG02, R265	6	30
CNBG_4692 (191)	E6R5B7	Nascent polypeptide-associated complex subunit-α	CG03, R265	5	30
CNBG_0959 (152)	E6R4T7	Cytoplasm protein	R265	4	30
CNBG_1632 (547)	E6R8N5	ATP synthase β-subunit	CG02, R265	14	29
CNBG_3753 (531)	E6RDZ5	Phosphoglycerate mutase	CG03	14	29

†*Position of the first amino acid of the epitope identified.*
‡*According to* **Table 1**.
§*Highest number of predicted peptides.*
WB: Western blot.

Table 2. Proteins and B-cell epitopes mapped by ABCPred and BCPreds algorithms identified by immunoblot sera from patients with cryptococcosis (cont.).

Protein ID (aa[†])	Accession code	Name of protein	WB strain[‡]	Epitopes (n)	Epitopes (%)[§]
CNBG_1355 (432)	E6QY25	Endopeptidase	CG02	11	29
CNBG_2617 (199)	E6RAJ9	40S ribosomal protein S7	R265	5	29
CNBG_5941 (158)	E6RBX1	Initiation factor 5a	CG03, R265	4	29
CNBG_0239 (614)	E6R0K8	Heat shock protein sks2	R265	15	28
CNBG_4851 (167)	E6RFA3	Cytoplasm protein	R265	4	28
CNBG_1185 (418)	E6QYK0	Succinyl-CoA ligase β-chain	CG02, CG03, R265	10	27
CNBG_2079 (420)	E6RA07	Mannitol-1-phosphate dehydrogenase	CG02	10	27
CNBG_0290 (251)	E6R0C0	Conserved hypothetical protein	CG01	6	27
CNBG_5765 (256)	E6RCQ9	14-3-3 protein	R265	6	27
CNBG_0379 (168)	E6R058	Ubiquitin carboxyl-terminal hydrolase	R265	4	27
CNBG_4912 (756)	E6RFH1	Heat shock protein (Hsp70)	CG01, CG02, R265	17	26
CNBG_2318 (175)	E6R9A9	Hypothetical protein	CG03	4	26
CNBG_4789 (135)	E6RF38	Conserved hypothetical protein	CG02	3	26
CNBG_0482 (408)	E6QZV4	Disulfide-isomerase	R265	9	25
CNBG_4625 (407)	E6R5I5	Pyruvate dehydrogenase e1 component β-subunit	CG01	9	25
CNBG_1460 (373)	E6QXQ4	3-isopropylmalate dehydrogenase	CG03, R265	8	25
CNBG_2499 (270)	E6RA79	Phosphomannomutase	CG03, R265	6	25
CNBG_6043 (233)	E6RCV4	Glutathione transferase	CG01	5	25
CNBG_0372 (291)	E6R068	Conserved hypothetical protein	CG03	6	24
CNBG_1816 (401)	E6R847	Ketol-acid reductoisomerase	R265	8	23
CNBG_5485 (152)	E6QZ59	Grx5-prov protein	CG03	3	23
CNBG_0257 (221)	E6R0I8	HHE domain-containing protein	R265	4	21
CNBG_0624 (125)	E6R3U6	Conserved hypothetical protein	CG02	2	18

[†]Position of the first amino acid of the epitope identified.
[‡]According to Table 1.
[§]Highest number of predicted peptides.
WB: Western blot.

Table 2. Proteins and B-cell epitopes mapped by ABCPred and BCPreds algorithms identified by immunoblot sera from patients with cryptococcosis (cont.).

Protein ID (aa†)	Accession code	Name of protein	WB strain‡	Epitopes (n)	Epitopes (%)§
CNBG_2132 (197)	E6R9V1	Thioredoxin peroxidase tpx1	CG01, CG02, R265	3	17
CNBG_3703 (433)	Q5KLA7	Phosphopyruvate hydratase (enolase)	CG01, R265	6	16

†*Position of the first amino acid of the epitope identified.*
‡*According to* Table 1.
§*Highest number of predicted peptides.*
WB: Western blot.

antigenicity in different strains, we believe that these proteins would be most promising for testing as antigens. However, after the analysis of the overlapping protein sequences in *C. gattii* (data not shown), we observed a high similarity (above 94%) between proteins from *C.gattii* genotypes VGI and VGII, except for the enolase protein (51%). Taken together, assessing the specificity of these antigens will be the next step to validate them for the diagnosis of cryptococcosis.

In addition, the fact that only six immunoreactive proteins were common to the three strains of *C. gattii* genotype VGII tested in our study is not surprising. For example, we recently demonstrated the significant genetic diversity of the *C. gattii* genotype VGII in Brazil using the multilocus sequence typing technique [57]. Of the six immunoreactive proteins identified here (Table 1), three are constitutive and involved in the cell cycle, cell division or the tricarboxylic acid cycle and were therefore excluded from this discussion.

Two of the three antigenic targets identified here, Hsp70 and GrpE, are members of the 70-kDa heat shock protein family. Hsp70 was identified as an antigenic target in sera from cryptococcosis patients infected with the strains CG01, CG02 and R265. This finding corroborates previous studies that identified proteins of the Hsp family as potential biomarkers for cryptococcosis [58–60]. Hsp70 is a phylogenetically conserved chaperone protein whose expression increases in response to temperature variation and environmental stress [61]. The role of this protein as an antigenic target in the context of cryptococcosis has been reported by various studies in both humans (by Rodrigues *et al.* [62]) and animal models in the clinical and subclinical phases (by Jobbins *et al.* [56] and Young *et al.* [55]), thus supporting our findings.

To our knowledge, this is the first report of the involvement of the second type of protein in the chaperone family with a size of 70 kDa (GrpE) as an antigenic target in the context of cryptococcosis. These new data have the potential to be used in the development of immunoassays because the same serum pool of neurocryptococcosis patients showed reactivity to GrpE in the three distinct strains of *C. gattii* genotype VGII.

The third protein identified in our study as an interesting antigenic target for the development of an immunoassay is the thiol peroxidase tpx1. We identified this protein in the aforementioned CG01, CG02 and R265 *C. gattii* genotype VGII strains. It is interesting to note that thiol peroxidase, a protein that acts to remove peroxides, also acts in response to oxidative stress, similar to Hsp70. Such proteins have previously been identified as being essential for intracellular survival, virulence and resistance to oxidative and nitrosative stress in *C. neoformans*, as reported by Missall *et al.* [63–65] and Wang *et al.* [66]. The finding presented here that thiol peroxidase is an antigenic target in *C. gattii* genotype VGII corroborates the findings of Jobbins *et al.* [56] and supports the hypothesis that this protein is involved in the pathogenesis of *C. gattii* genotype VGII infection in humans [62,67–69].

Other important proteins identified in the current study include the following: enolase and ATP synthase (found in strains CG01 and R265); phosphomannomutase (strains CG03 and R265); aconitase and Wos2 (strain CG02); and cofilin and CAN2 (strain CG03).

Enolase and ATP synthase appear to be important in the process of host invasion by the fungus. During the invasion of the brain and the CNS, penetration of the blood–brain barrier is a prerequisite for the establishment of meningoencephalitis by the opportunistic fungal pathogen *C. neoformans*. The fungal cells require a high level of energy to traverse this barrier, and enolase, which is an enzyme in the glycolysis pathway, could be essential for this purpose during the infection process [58]. In addition, the relative importance of plasminogen in infectious diseases is indicated by the surface-associated plasminogen-binding properties manifested by diverse species of human pathogens. Several

proteins, including enolase, have been found to play a major role in the microbial recruitment of plasminogen [68].

Phosphomannomutase can be considered to be an indirect virulence factor for *Cryptococcus* spp. This statement is justified by the fact that this enzyme is responsible for the synthesis of mannose, which is a carbohydrate comprising up to two-thirds of the main cryptococcal virulence factor, the polysaccharide capsule. The capsular polysaccharide of *C. neoformans* helps to protect yeast against the host immune system due to its function as either an antiphagocytic factor and/or an antigenic polysaccharide that is extruded into tissue and fluids and produces an immunosuppressive effect. The capsular polysaccharide, GXM, comprises three major sugars: mannose, xylose and glucuronic acid. The identification of this protein as an antigenic target is not surprising because it is involved in the production of mannoprotein–mannose complexes that elicit a cytokine-mediated inflammatory immune response. Important factors for proliferation in host tissue include enzymes involved in central carbon metabolism (gluconeogenesis and acetylCoA synthesis), regulators of capsule and melanin synthesis and proteins involved in resistance to phagocytosis [17,70–72].

The identification of the proteins aconitase (an enzyme involved in the metabolism of carbohydrates) and Wos2 (a cochaperone of Hsp90) corroborates the results of a study by Crestani *et al.* [73], which showed that aconitase and Wos2 expression levels increase in *C. gattii* (strain R265) in response to a lack of iron in the culture medium. It is important to note that the common factors between our study and that of Crestani *et al.* [73] are the stress conditions to which *C. gattii* was exposed and that Wos2 has been suggested to be an early marker of *C. gattii* infection in koalas [56]. Similar to enolase, the protein cofilin identified herein may play a relevant role in the process of the fungus spreading to the CNS. The rationale for this hypothesis is that cofilin interferes with the polymerization of F-actin and G-actin strands, thereby modulating the cytoskeleton of the target cell. This idea is in accordance with the results reported by Wang *et al.* [66], who demonstrated differential expression of cofilin in human umbilical vascular endothelial cells infected by *C. neoformans*.

The identification of CAN2 as an antigenic target in the context of cryptococcosis may be explained, at least in part, by this protein experiencing an increase in pressure in response to the change in the environmental CO_2 tension (0.033%) relative to that found in the host (5%). This protein works as a sensor for this CO_2 tension change and alerts the cell to the need for capsule thickening. This thickening is, in turn, an important virulence mechanism in cryptococcosis [74,75].

Importantly, the applied B-cell epitope prediction was efficient because the majority of the proteins (85.4%) presented a high percentage of epitopes. The high percentage of epitopes in nearly all of the identified proteins can be explained by the selection based on western blot analysis. It is important to highlight the fact that two proteins that were previously defined as hypothetical proteins showed a higher percentage (>42%) of epitopes. These hypothetical proteins exhibit a conserved homology in other species of *Cryptococcus*. The identified epitopes can be produced as synthetic peptides and could be tested for use in the diagnosis of cryptococcosis.

Conclusion

In conclusion, the applied combination of immunoproteomics and immunoinformatics methods was demonstrated to be a specific and powerful tool for identifying novel antigens from mycological pathogens. The major finding of this work was the identification of *C. gattii* proteins recognized as molecular targets by antibodies produced by patients with cryptococcal meningitis. In addition, we identified potential antigens that may be used for the development of more accurate serological diagnoses in human cryptococcal meningitis.

Future perspective

Cryptococcosis caused by *C. gattii* genotype VGII has resulted in significant repercussions over the years owing to the occurrence of outbreaks in Canada, mainly affecting immunocompetent individuals, causing high morbidity and mortality. Therefore, significant efforts have been devoted to the search for diagnostic tests that are sensitive, specific and can detect infection as early as possible. The immunogenic proteins and B-cell epitopes identified herein need to be investigated as antigens in serological tests to diagnose cryptococcal infection. These proteins could present cross-reaction with cryptococcal infection caused by other species. Although these proteins can react with multiple fungal species, some of these fungi may not be present in the patient. However, this is the first important step to selecting new target antigens to facilitate the immunodiagnosis of cryptococcosis.

Executive summary

Objectives of the study

- The objective was to identify immunoreactive proteins using sera from patients with cryptococcosis.
- The study aimed to map B-cell epitopes from immunoreactive proteins from *Cryptococcus gattii* genotype VGII.

Methods

- 2D gel electrophoresis integrated with immunoblotting and mass spectrometry was used to identify immunoreactive proteins.
- ABCPred and BCPreds programs were utilized to predict epitopes for B cells.

Conclusion

- A total of 68 immunoreactive proteins were identified.
- The ABCPred and BCPreds programs generated 374 concordant peptides.
- The Hsp70, thioredoxin peroxidase and GrpE proteins were immunoreactive in at least three strains of *C. gattii* genotype VGII.

Acknowledgements

The authors would like to sincerely thank JFR Estanislau from the Unit of Protein Chemistry and Mass Spectrometry (MS-UniProt, Biotechnology Center, UFRGS, Brazil) for operating the mass spectrometer and J Batista de Oliveira Silva Jr for translation of the manuscript into English. The authors also thank M do Amparo Salmito Cavalcanti for contributing to the acquisition of the clinical data for the subjects involved in the research and the patients in this study. The authors also thank the Renorbio Postgraduate Program for its research incentive in the northeastern region of Brazil.

Financial & competing interests disclosure

This work was supported by the Laboratory of Immunogenetics and Molecular Biology (LIB), Federal University of Piauí, Brazil. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The revision of the English language of this manuscript was performed by American Journal Experts, funded by the Laboratory of Immunogenetics and Molecular Biology (LIB), Federal University of Piaui, Brazil.

Ethical conduct of research

The study protocol was approved by the State University of Piauí-Brazil Institutional Review Board (CEP 079/2008) and by the Brazilian National Ethics Committee (CONEP). All patients enrolled in the study signed forms providing free and informed consent.

References

Papers of special note have been highlighted as:
▪ of interest
▪▪ of considerable interest

1. Springer DJ, Chaturvedi V. Projecting global occurrence of *Cryptococcus gattii*. *Emerg. Infect. Dis.* 16(1), 14–20 (2010).
2. Del Poeta M, Casadevall A. Ten challenges on *Cryptococcus* and cryptococcosis. *Mycopathologia* 17(5–6), 303–310 (2012).
3. Chaturvedi V, Chaturvedi S. *Cryptococcus gattii*: a resurgent fungal pathogen. *Trends Microbiol.* 19(11), 564–571 (2011).
4. Harris J, Lockhart S, Chiller T. *Cryptococcus gattii*: where do we go from here? *Med. Mycol.* 50(2), 113–129 (2012).
5. Bartlett KH, Cheng PY, Duncan C *et al.* A decade of experience: *Cryptococcus gattii* in British Columbia. *Mycopathologia* 173(5–6), 311–319 (2012).
6. Trilles L, Meyer W, Wanke B, Guarro J, Lazera M. Correlation of antifungal susceptibility and molecular type within the *Cryptococcus neoformans*/*C. gattii* species complex. *Med. Mycol.* 50(3), 328–332 (2012).
7. Espinel-Ingroff A, Aller AI, Canton E *et al.* *Cryptococcus neoformans–Cryptococcus gattii* species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. *Antimicrob. Agents Chemother.* 56(11), 5898–5906 (2012).
8. Lockhart SR, Iqbal N, Cleveland AA *et al.* Species identification and antifungal susceptibility testing of *Candida* bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. *J. Clin. Microbiol.* 50(11), 3435–3442 (2012).
9. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M *et al.* *Cryptococcus neoformans–Cryptococcus gattii* species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. *Antimicrob. Agents Chemother.* 56(6), 3107–3113 (2012).
10. Thompson GR 3rd, Fothergill AW, Wiederhold NP, Vallor AC, Wickes BL, Patterson TF. Evaluation of Etest method for determining isavuconazole MICs against *Cryptococcus gattii* and *Cryptococcus neoformans*. *Antimicrob. Agents Chemother.* 52(8), 2959–2961 (2008).
11. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of *Cryptococcus gattii* and *Cryptococcus neoformans*. *Antimicrob. Agents Chemother.* 53(1), 309–311 (2009).
12. Bovers M, Hagen F, Boekhout T. Diversity of the *Cryptococcus neoformans–Cryptococcus gattii* species complex. *Rev. Iberoam. Micol.* 25(1), S4–S12 (2008).
13. Leal AL, Faganello J, Bassanesi MC, Vainstein MH. *Cryptococcus* species identification by multiplex PCR. *Med. Mycol.* 46(4), 377–383 (2008).
14. Posteraro B, Vella A, Cogliati M *et al.* Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based method for discrimination between molecular types of *Cryptococcus neoformans* and *Cryptococcus gattii*. *J. Clin. Microbiol.* 50(7), 2472–2476 (2012).
15. Firacative C, Trilles L, Meyer W. MALDI-TOF MS enables the rapid identification of the major molecular types within the *Cryptococcus neoformans*/*C. gattii* species complex. *PLoS ONE* 7(5), e37566 (2012).
16. McTaggart LR, Lei E, Richardson SE, Hoang L, Fothergill A, Zhang SX. Rapid identification of *Cryptococcus neoformans* and *Cryptococcus gattii* by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J. Clin. Microbiol.* 49(8), 3050–3053 (2011).

17. Kronstad JW, Attarian R, Cadieux B *et al.* Expanding fungal pathogenesis: *Cryptococcus* breaks out of the opportunistic box. *Nat. Rev. Microbiol.* 9(3), 193–203 (2011).
18. D'Souza CA, Kronstad JW, Taylor G *et al.* Genome variation in *Cryptococcus gattii*, an emerging pathogen of immunocompetent hosts. *MBio* 2(1), e00342-10 (2011).

▪ **Excellent article for understanding the pathogenesis of cryptococcosis.**

19. Byrnes EJ 3rd, Li W, Lewit Y *et al.* First reported case of *Cryptococcus gattii* in the southeastern USA: implications for travel-associated acquisition of an emerging pathogen. *PLoS ONE* 4(6), e5851 (2009).
20. Kidd SE, Hagen F, Tscharke RL *et al.* A rare genotype of *Cryptococcus gattii* caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). *Proc. Natl Acad. Sci. USA* 101(49), 17258–17263 (2004).
21. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for *Cryptococcus gattii* infection, British Columbia, Canada. *Emerg. Infect. Dis.* 17(2), 193–199 (2011).
22. Chowdhary A, Randhawa HS, Boekhout T, Hagen F, Klaassen CH, Meis JF. Temperate climate niche for *Cryptococcus gattii* in northern Europe. *Emerg. Infect. Dis.* 18(1), 172–174 (2012).
23. Hagen F, Colom MF, Swinne D *et al.* Autochthonous and dormant *Cryptococcus gattii* infections in Europe. *Emerg. Infect. Dis.* 18(10), 1618–1624 (2012).
24. Colom MF, Hagen F, Gonzalez A *et al.* *Ceratonia siliqua* (carob) trees as natural habitat and source of infection by *Cryptococcus gattii* in the Mediterranean environment. *Med. Mycol.* 50(1), 67–73 (2012).
25. Darze C, Lucena R, Gomes I, Melo A. The clinical laboratory characteristics of 104 cases of cryptococcal meningoencephalitis. *Rev. Soc. Bras. Med. Trop.* 33(1), 21–26 (2000).
26. Martins LM, Wanke B, Lazera Mdos S *et al.* Genotypes of *Cryptococcus neoformans* and *Cryptococcus gattii* as agents of endemic cryptococcosis in Teresina, Piaui (northeastern Brazil). *Mem. Inst. Oswaldo Cruz* 106(6), 725–730 (2011).

▪ **Characterization of cryptococcosis as an important fungal disease in immunocompetent children and young adults in northeastern Brazil caused by *Cryptococcus gattii* genotype VGII.**

27. Nishikawa MM, Lazera MS, Barbosa GG *et al.* Serotyping of 467 *Cryptococcus neoformans* isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns. *J. Clin. Microbiol.* 41(1), 73–77 (2003).
28. Santos WR, Meyer W, Wanke B *et al.* Primary endemic *Cryptococcosis gattii* by molecular type VGII in the state of Para, Brazil. *Mem. Inst. Oswaldo Cruz* 103(8), 813–818 (2008).
29. Severo CB, Xavier MO, Gazzoni AF, Severo LC. Cryptococcosis in children. *Paediatr. Respir. Rev.* 10(4), 166–171 (2009).
30. Galanis E, MacDougall L. Epidemiology of *Cryptococcus gattii*, British Columbia, Canada, 1999–2007. *Emerg. Infect. Dis.* 16(2), 251–257 (2010).
31. Lindsley MD, Mekha N, Baggett HC *et al.* Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. *Clin. Infect. Dis.* 53(4), 321–325 (2011).
32. McMullan BJ, Halliday C, Sorrell TC *et al.* Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. *PLoS ONE* 7(11), e49541 (2012).
33. Hansen J, Slechta ES, Gates-Hollingsworth MA *et al.* Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. *Clin. Vaccine Immunol.* 20(1), 52–55 (2012).
34. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E. Molecular typing of IberoAmerican *Cryptococcus neoformans* isolates. *Emerg. Infect. Dis.* 9(2), 189–195 (2003).
35. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72, 248–254 (1976).
36. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227(5259), 680–685 (1970).
37. Neuhoff V, Arold N, Taube D, Ehrhardt W. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. *Electrophoresis* 9(6), 255–262 (1988).
38. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. *Proteins* 65(1), 40–48 (2006).
39. El-Manzalawy Y, Dobbs D, Honavar V. Predicting linear B-cell epitopes using string kernels. *J. Mol. Recognit.* 21(4), 243–255 (2008).
40. Faria AR, Costa MM, Giusta MS *et al.* High-throughput analysis of synthetic peptides for the immunodiagnosis of canine visceral leishmaniasis. *PLoS Negl. Trop. Dis* 5(9), e1310 (2011).
41. Costa MM, Andrade HM, Bartholomeu DC *et al.* Analysis of *Leishmania chagasi* by 2-D difference gel electrophoresis (2-D DIGE) and immunoproteomic: identification of novel candidate antigens for diagnostic tests and vaccine. *J. Proteome Res.* 10(5), 2172–2184 (2011).

▪ **Illustrates the proteomic and *in silico* analysis used to identify novel proteins and peptides for diagnostic tests.**

42. Pedersen SK, Sloane AJ, Prasad SS *et al.* An immunoproteomic approach for identification of clinical biomarkers for monitoring disease: application to cystic fibrosis. *Mol. Cell Proteomics* 4(8), 1052–1060 (2005).
43. Zhu YZ, Cai CS, Zhang W *et al.* Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV). *PLoS ONE* 5(11), e13915 (2010).
44. Tjalsma H, Schaeps RM, Swinkels DW. Immunoproteomics: from biomarker discovery to diagnostic applications. *Proteomics Clin. Appl.* 2(2), 167–180 (2008).
45. Hess JL, Blazer L, Romer T, Faber L, Buller RM, Boyle MD. Immunoproteomics. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 815 (1–2), 65–75 (2005).
46. Santi L, Silva WO, Pinto AF, Schrank A, Vainstein MH. *Metarhizium anisopliae* host–pathogen interaction: differential immunoproteomics reveals proteins involved in the infection process of arthropods. *Fungal Biol.* 114(4), 312–319 (2010).
47. Liao Y, Deng J, Zhang A *et al.* Immunoproteomic analysis of outer membrane proteins and extracellular proteins of *Actinobacillus pleuropneumoniae* JL03 serotype 3. *BMC Microbiol.* 9, 172 (2009).
48. Yang Y, Wang L, Yin J *et al.* Immunoproteomic analysis of *Brucella melitensis* and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. *Mol. Immunol.* 49(1–2), 175–184 (2011).
49. Wu Z, Zhang W, Lu C. Immunoproteomic assay of surface proteins of *Streptococcus suis* serotype 9. *FEMS Immunol. Med. Microbiol.* 53(1), 52–59 (2008).
50. Saisongkorh W, Kowalczewska M, Azza S, Decloquement P, Rolain JM, Raoult D. Identification of candidate proteins for the diagnosis of *Bartonella henselae* infections using an immunoproteomic approach. *FEMS Microbiol. Lett.* 310(2), 158–167 (2010).
51. Lopez JE, Porcella SF, Schrumpf ME *et al.* Identification of conserved antigens for early

serodiagnosis of relapsing fever *Borrelia*. *Microbiology* 155(Pt 8), 2641–2651 (2009).

52. Altindis E, Tefon BE, Yildirim V *et al.* Immunoproteomic analysis of *Bordetella pertussis* and identification of new immunogenic proteins. *Vaccine* 27(4), 542–548 (2009).
53. Bunk S, Susnea I, Rupp J *et al.* Immunoproteomic identification and serological responses to novel *Chlamydia pneumoniae* antigens that are associated with persistent *C. pneumoniae* infections. *J. Immunol.* 180(8), 5490–5498 (2008).
54. Al Dahouk S, Nockler K, Scholz HC, Tomaso H, Bogumil R, Neubauer H. Immunoproteomic characterization of *Brucella abortus* 1119-3 preparations used for the serodiagnosis of *Brucella* infections. *J. Immunol. Methods* 309(1–2), 34–47 (2006).
55. Young M, Macias S, Thomas D, Wormley FL Jr. A proteomic-based approach for the identification of immunodominant *Cryptococcus neoformans* proteins. *Proteomics* 9(9), 2578–2588 (2009).

▪▪ **Protein identification involved in the pathogenesis of cryptococcosis.**

56. Jobbins SE, Hill CJ, D'Souza-Basseal JM, Padula MP, Herbert BR, Krockenberger MB. Immunoproteomic approach to elucidating the pathogenesis of cryptococcosis caused by *Cryptococcus gattii*. *J. Proteome Res.* 9(8), 3832–3841 (2010).

▪▪ **Immunoproteomic approach for the identification of *Cryptococcus gattii* immunoreactive proteins in an animal model.**

57. Trilles L, Souto AC, Barbosa GG *et al.* Multilocus sequence typing reveals a high genetic diversity among the Brazilian VGII population. Presented at: *8th International Conference on* Cryptococcus *and Cryptococcosis*. Charleston, SC, USA, 1–5 May 2011.
58. Kakeya H, Udono H, Maesaki S *et al.* Heat shock protein 70 (Hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. *Clin. Exp. Immunol.* 115(3), 485–490 (1999).
59. Kakeya H, Udono H, Ikuno N *et al.* A 77-kilodalton protein of *Cryptococcus neoformans*, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. *Infect. Immun.* 65(5), 1653–1658 (1997).
60. Steen BR, Zuyderduyn S, Toffaletti DL *et al.* *Cryptococcus neoformans* gene expression during experimental cryptococcal meningitis. *Eukaryot. Cell* 2(6), 1336–1349 (2003).
61. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. *Cell. Mol. Life Sci.* 62(6), 670–684 (2005).
62. Rodrigues ML, Nakayasu ES, Oliveira DL *et al.* Extracellular vesicles produced by *Cryptococcus neoformans* contain protein components associated with virulence. *Eukaryot. Cell* 7(1), 58–67 (2008).

▪▪ **Identifies proteins associated with the virulence of *Cryptococcus neoformans*.**

63. Missall TA, Pusateri ME, Lodge JK. Thiol peroxidase is critical for virulence and resistance to nitric oxide and peroxide in the fungal pathogen, *Cryptococcus neoformans*. *Mol. Microbiol.* 51(5), 1447–1458 (2004).
64. Missall TA, Moran JM, Corbett JA, Lodge JK. Distinct stress responses of two functional laccases in *Cryptococcus neoformans* are revealed in the absence of the thiol-specific antioxidant Tsa1. *Eukaryot. Cell* 4(1), 202–208 (2005).
65. Missall TA, Pusateri ME, Donlin MJ, Chambers KT, Corbett JA, Lodge JK. Posttranslational, translational, and transcriptional responses to nitric oxide stress in *Cryptococcus neoformans*: implications for virulence. *Eukaryot. Cell* 5(3), 518–529 (2006).
66. Wang XJ, Zhu YJ, Cui JG *et al.* Proteomic analysis of human umbilical vein endothelial cells incubated with *Cryptococcus neoformans* var. *neoformans*. *Mycoses* 54(5), e336–e343 (2011).
67. Rodrigues ML, Nimrichter L, Oliveira DL, Nosanchuk JD, Casadevall A. Vesicular trans-cell wall transport in fungi: a mechanism for the delivery of virulence-associated macromolecules? *Lipid Insights* 2, 27–40 (2008).
68. Nosanchuk JD, Nimrichter L, Casadevall A, Rodrigues ML. A role for vesicular transport of macromolecules across cell walls in fungal pathogenesis. *Commun. Integr. Biol.* 1(1), 37–39 (2008).
69. Biondo C, Mancuso G, Midiri A *et al.* Identification of major proteins secreted by *Cryptococcus neoformans*. *FEMS Yeast Res.* 6(4), 645–651 (2006).
70. De Jesus M, Chow SK, Cordero RJ, Frases S, Casadevall A. Galactoxylomannans from *Cryptococcus neoformans* varieties *neoformans* and grubii are structurally and antigenically variable. *Eukaryot. Cell* 9(7), 1018–1028 (2010).
71. Cottrell TR, Griffith CL, Liu H, Nenninger AA, Doering TL. The pathogenic fungus *Cryptococcus neoformans* expresses two functional GDP-mannose transporters with distinct expression patterns and roles in capsule synthesis. *Eukaryot. Cell* 6(5), 776–785 (2007).
72. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen *Cryptococcus neoformans*. *Adv. Appl. Microbiol.* 68, 133–216 (2009).
73. Crestani J, Carvalho PC, Han X *et al.* Proteomic profiling of the influence of iron availability on *Cryptococcus gattii*. *J. Proteome Res.* 11(1), 189–205 (2011).
74. Mogensen EG, Janbon G, Chaloupka J *et al.* *Cryptococcus neoformans* senses CO_2 through the carbonic anhydrase CAN2 and the adenylyl cyclase CAC1. *Eukaryot. Cell* 5(1), 103–111 (2006).
75. Kozubowski L, Lee SC, Heitman J. Signalling pathways in the pathogenesis of *Cryptococcus*. *Cell Microbiol.* 11(3), 370–380 (2009).

Websites

101. Matrix Science. Mascot software. www.matrixscience.com
102. Broad Institute Protein Database. www.broadinstitute.org/annotation/genome/cryptococcus_neoformans_b/MultiHome.html
103. Blast2GO. Software for Biologists. www.blast2go.org
104. National Center for Biotechnology Information (NCBI) BLAST database. http://blast.ncbi.nlm.nih.gov/Blast.cgi
105. ABCPred. Artificial neural network-based B-cell epitope prediction server. www.imtech.res.in/raghava/abcpred
106. Iowa State University. Department of Computer Science. Artificial Intelligence Research Laboratory. BCPreds. http://ailab.cs.iastate.edu/bcpreds

Future Microbiol. 2013 Apr;8(4):549-63. doi: 10.2217/fmb.13.22.

Immunoproteomics and immunoinformatics analysis of Cryptococcus gattii: novel candidate antigens for diagnosis

Liline Maria Soares Martins [1], Hélida Monteiro de Andrade, Marilene Henning Vainstein, Bodo Wanke, Augusto Schrank, Claudia Bemfica Balaguez, Patrícia Ribeiro dos Santos, Lucélia Santi, Simone da Fonseca Pires, Adalberto Socorro da Silva, José Adail Fonseca de Castro, Rafael Melo Santos de Serpa Brandão, Semiramis Jamil Hadad do Monte

Affiliations
PMID: 23534365 DOI: 10.2217/fmb.13.22

Free article

Abstract

Aim: To identify immunoreactive proteins of Cryptococcus gattii genotype VGII and their B-cell epitopes.

Materials & methods: We combined 2D gel electrophoresis, immunoblotting and mass spectrometry to identify immunoreactive proteins from four strains of C. gattii genotype VGII (CG01, CG02, CG03 and R265). Next, we screened the identified proteins to map B-cell epitopes.

Results: Sixty-eight immunoreactive proteins were identified. The strains and the number of proteins we found were: CG01 (12), CG02 (12), CG03 (18) and R265 (26). In addition, we mapped 374 peptides potentially targeted by B cells.

Conclusion: Both immunoreactive proteins and B-cell epitopes of C. gattii genotype VGII that were potentially targeted by a host humoral response were identified. Considering the evolutionary relevance of the identified proteins, we may speculate that they could be used as the initial targets for recombinant protein and peptide synthesis aimed at the development of immunodiagnostic tools for cryptococcosis.

Related information

MedGen

LinkOut - more resources

Full Text Sources
Atypon
Ovid Technologies, Inc.

Other Literature Sources
scite Smart Citations

Table S2: Accession numbers of each immunoreactive protein with their overlapping peptides obtained from BCPreds and ABCPred.

CNBG_1632
AIRLSRRGGQQLKN
QAKNIVPKFAASSS
ARTYATPAGLQTGS
VDVHFDSDNLPPIL
VQFGEGQTAPEGGR
APIKIPVGPATLGR
IDQRGPIKGVKEAP
HADAPEFVDQSTQA
TGVGERTREGNDLY
GQMNEPPGARARVA
AEYFRDEEGQDVLL
QERITTTKKGSITS
TDPAPATTFAHLDA
MLDPRVVGQRHYEI

CNBG_0372
RQRFEPDVGGDSGS
TQQPQNGTAYAPTY
VEEVWERAWNTAGR
HPKCYKDAQKGNGV
EPTSMLQRESNCPK
LPSTTATWDRIFRP

CNBG_0379
EASPDVFNAIPNAC
LPERGPDALNPDSK
TNAAQTGQSVVPTD
DVAKVVQEKYFERA

CNBG_1079
LKKMATEQLENALN
GNNNYSSGNNTQGS
SQQRYGGNQNQSYG
SQNQGYGQQPGGYG
GGYGQQENYGGQNQ
GGAQYNRPHGQGGA
AANEHNSNGNENSS
LSFIGNMNKNDTDI
AYGQGNTSGMTSSS
AADTSGNKQGGGDM
FDSSGGNIQGNKQD

CNBG_0239
EGAIGIDLGTTYSC
TTPSYVAFTEGERL
RRYDDADVKKDMKH
VIDKDGSPYVEVDY
NEKKTFSPQEISAM
EVLRIINEPTAAAI
IFDLGGGTFDVSLL
GDTHLGGEDFDNNL
HFKAEFKRKTKLDI
TAFKSTVDPVDKVL
SINPDEAVAYGAAV
VLPRNTPIPSNKSR
PVYEGERTQCKDNR
GIPPMPRGQAELVC
DRASGRKAQITIQN

CNBG_4560
DSTLPAVPKGPPTP
KLTTEAATEWASLT
EFWNSTTPETRAAI
GKKVSPPGGKKAFK
RPGNPGKPLTPYFA
KEIRDSGKINVSSD

CNBG_3163
APLHPEITYAERSS
INAPDVQDKYNLDI
EKEYSFDLQLWGEI
KEAQAEYWPRLTKE
SKWVDEDEQEGTED
AGMEGMEGMGGMGG
GGMGGMPGMGGMGG
SKLMEQMGGMGAMG

CNBG_1185
MIRGFKQARAAVKP
VQLLNSYGIPTPKA
QGGVQMVDTPAQAK
MLGHKLITKQTGAA
LAERMPPQKEYYAA
LNDRTTGGPVLVTS
IFKEKDSTQIEINP
TTQEDAQEVEAAKY
NFIKLDGDIGCLVN
DVGGGATADAVKKA

CNBG_5765
AKLAEQAERYEEMV
VASSDQELTVEERN
EQKEESKGNEAQVA
EFATGDKRKDSADK
VTELPPTHPIRLGL
LDTLSEESYKDSTL

CNBG_1816
LSGAAPRAAMATRL
KEVVYERADWPLDK
SWKQAQEDGWVPGE
SVVYKEDTHVIPPK
VAPKGSGRTVRTLF
ETTFEKEVYSDLYG
GVLMGGIQGMFLAQ
YMYNACSTTARRGA

CNBG_5509
MSDQNDQASTFTPI
NMEQPKSWSSTIGM
NWDNDKIVFSKRSL
AEIADPTTESSILP
SLAPPRDGGDGVDV
ERMKMHVEPEQEGG

CNBG_1866
MVVKVGINGFGRIG
FKYDSTHGRFKGSV
EKDPANIKWGDAGA
APSADAPMFVCGVN
KIVSNASCTTNCLA
LMTTVHATTATQKT
RGGRGAAANIIPSS
GMSFRVPTSDVSVV
STDFVGSTESSIFD

CNBG_2617
ANAPQTAPSEIEQQ
SAKEVDVKGGKKAV
VPVPMVKAFHKVQQ
SAQKQKRPRSRTLT
EIVGKRTRVAQDGS

CNBG_2132
ALPQIQKPAPDFAG
RSEGGLGPDLRLTL
LRGTFFIDPKGTLR

CNBG_0282
RTSSQDGTIKEDDK
DPDSAEDDKAYSIK
KTKAKSFASASPHS
KVKAESLKTKGNNL
EKALELDPKFTKAY
FSLGNYSDAVKAYE
LELDPSNANMKTAL
EPPRNDNGNGGGMP
GGSGNGGMPDLASM
SNPQMMAMAQQMMA

CNBG_1302
AKHAVPHSHEKADI
EHAPKVTPGKENVQ
DRAVASDDPKDVNP
SKKEGKGDKAGEDQ
PEAKSGGASANETA
QKSANANKGEEKTE
KQQGSEEGAPSAQD
VTHVMVVGHTGCGG
PTEENPGATPLVRY

CNBG_2923
TADKLPKALQATED
CHLGTKNCDKSMEN
ISARPYGHRAVLKY
IAGRFTPGSFTNYI
DPRVDHQAIREAAY
VGLMWYLLCREVLR
RGTVPRGPTGPSGW
FYRDPEEIEREAAE
AAAQEGADAEAAAT

CNBG_0290
RAGDCGGVGETDGT
YELESAAAQPEVPA
EDSEAPASGPASIT
ETCDEGFEITNVAV
DAKGAEGDWERRSR
GPQFDHLDETVQEA

CNBG_2079
KTTFRTIHTTQAKM
SNFTIPKTQTAAVV
IDKEHPVRQASELK
CHTDLHAKSGDWPV
EYVVSFVNHVTPIP
TTYKALKVSNTKVN
PGAGGGLGHLAVQY
KAATGGDGPTAAVV
AANKTGYTQAVEYL
FKSIRIQGSYVG

CNBG_0257
DHREIEQYYDQIIN
ADRDRQEHQKVKEM
SPSDNQFEPTIKRL
SDLAEHIKEEETED

CNBG_0624
WSTDGKISHTTAEV
YRDTDGEWTPDKNE

CNBG_4548
EEIDMDLEHSVAAQ
GNRYWARKVTSEEP
MAEQVKGQAPNFLW
TVMDRKPGEVFVQR
VANQFKPEDDSSQA
AVKNVVNSPTIQGA
KARKGEFREVFVHG

CNBG_6164
DFLVGNYATPDMFT
ENEAKKVEYFSKFP
GCGTQSEPVAKAVN
GVHPTFPAPDDADR
VESKNPGKNFFKHY

CNBG_4027
GHDGHEGPRPDIPA
RGHIGRTNALPTTP
TTRNVPAAASSSAT
FSPYRAKNPNTTRN
GKNLIVKWRGKPVF
HRTPDEIEEANSVD
RDPETDEQRTQRPE
GCVPIGEAGDYGGW

CNBG_4625
APLSTSAPSPASAK
LTTAAPKVPRSASR
VGEGQKRAASSDEG
FGEDRVIDTPITEA
GLRPICEFMTWNFA
VPCPVVFRGPNGAA
HSQDYCAWYGSVPG
EVVNLRSIRPLDIE
ITVEGGFPAFGVGS

CNBG_0482
DLDTTNFDQIIGQD
ELWCGHCKNLAPTY
GVSGFPTLKWFPAG
EPIPYSGARDLETL
NIKPPPPPAYTELD
TAPWCGHCKNMKPA
DDAENKPVAQRYGV
VPYDSGRTAEQFVD
SEIVKKAQETVTTL

CNBG_1460
TILPGDGIGPEVVA
GSVGGPKWGVGPVR
LGLYANIRPANFAS
GERQETNDEGVAWD
AAEPPLPITSVDKA
KEYPQLKLEHQLVD
AGAPDPNSTTMGLY
PIHGSAPDIAGQGI

CNBG_3378
RSYVDGFKPTTADV
EFDTLPAGTNPFSS
AEEDDEVDLFGSDD
NEAKEAKKQEKLAA
LVPVGYGIKMLQIN

CNBG_4789
AVVYKPNEYADEYM
DDVADYERWKDGAK
PSRGAGDTRATGAS

CNBG_0705
GHLDNPHEQDIERG
KLRPDRVACQDATA
AGLPQTAVPTSVHC
RAIDINKEVYDFLA
HQIILENYAVPGLM
MVACGVGGADAVDV
YLDGKMSGWTTPKD
GTGAIIEYHGPGVE
KATNRPAIAQYAEE
HNLQPDQGCEYDQR
PHINGPFTPDLATP
SKFADEVKRHSWPQ
GLIGSCTNSSYEDM
DGMVEDFEKVGGVV
ANACGPCIGQWDRR
NRNFTGRNDANPAT
IFAGDLTFNPMTDS
KGADGKEFRFSDPS
YELPAKGYDPGENT
QAPPADGTTVSVAV
IKAKGKCTTDHISA
IGAINADNGEANKV
EYGPVPTVGAYYRD

CNBG_4912
PAKTAETSNFKNTI
RSVNDPEVEEFEKK
VDVNGEIGVKVNYL
VLCSTPPTLPGLNA
GHSDYSVAVVAFSK
RHFGGRDFDYALVQ
FRLTTGCERLKKVL
QDEAIARGATFACA
KEAGNPDEDTELVV
TANPIPSTKVLTFY
EASYADPATLPKGI
EEEVTVGEGEDAKT
KKIQRKGDCPVVGQ
KEALLQGLQEAEDW
EEGEDASKSAYVQK
RWKESEERPKAAAA
TYLTAAQGEDEKYS

CNBG_5941
MAEEEHHETFEATG
STSKTGKHGHAKVH
SPSTHNMDVPNVRR
MDSDGGSKDDVKVP

CNBG_5485
RSLPQSQVARSTTI
KGTPDAPQCGFSRA
EGIKEYSEWPTIPQ

CNBG_0959
MAEPFDANTAGNAE
KGKERWRKFIMPYE
GTLVRRRSDELYTQ

CNBG_3753
TRPPTSPNADDANK
KGNAIFHGDTTHMD
DQSIKKDEFKDQPA
IDAMKHAKETSGRL
SDGGVHSHIQHLFA
FFGDGRDTAPKSAT
GRYYAMDRDKRWDR
KGEGEKTDQEGLIK
SGSEDSRIKKGDSL
PDKPMEVDVPEDLH
EFPFPVAFPPQGMT
EKQFENEQREMIPS
PPDMVGHTGDYDAA
DAAVKTVYDACEEA

CNBG_3631
EKFQELKTGKKLAY
KASEDKDFDSFVAE
DYEFTLPGGEGVRN
CFIVWSPDDASVKS

CNBG_2318
RGFGFVTYGSPQEA
EQELDGRRVRVNMA
GGGGYGGGYNSGYG
QQGGYQQGGGFNQG

CNBG_2499
PQPASATIFPPNVK
ASFIKHVGEEEYKK
SPIGRNASIQERID
EKYDKEHGIRADMV
SFDVFPKGWDKTYA
RHIEGEGFETIHFF

CNBG_3703
TEKGLFRAEVPSGA
AVELRDKGSDYMGK
AANVGDEGGFAPNV
SEFFKDGKYDLDFK
SIEDPFHEDDFDAW
SHRSGETESTYIAD

CNBG_4692
LHSRPERKARKALE
VLLVVANPEVYKSP
FGEAKVEDPNSAAQ
QAHAHGGFKEGVPK
DEPSADSSAPAPSG

CNBG_5365
VNVGWPYGTNKIRG
LKNHWDTWFTENDF
AYDVQGGEPYIQGQ
HGAPGSQNGYDNSG
NADWATDNTNVERT
SQKYSDPQYYGVVT
LLNEPATYLNDQLL
RQYWYDAYGAARYP
TFDNYMVEPEYEDV
SNVCNQASTYSSSP
GRGINARYDGSYPG
SCDDKSNDVSTFSN

CNBG_5600*

CNBG_3060
MNPRSLTTAVRSFT
AARTFTPQLQARAY
RADVQTAVRRSAEE
TALKHVPQPIPAEN
LKTFESHGVKKLEN
AVAPKKDNGEPHGP

CNBG_0115
RPSKPSDGKVNEQG
NVQGDKRYHFEFEK
EKSTQEEVFEHVEP
QGTKEEPGLIPRAV
RTEPRKREIRMSAG
DLIHQPISSWEEFE
YDTASKTRKTASTK
ESSDKVNHGKICFT
NNNLTGNDRERMRE
IAQKGGDGTGVFVPY
NTLHFGKKSKTVEN
DRRGKAQILENFRR
NLKTINPQAPFKIH
APLIPNVCHKKQNL
GSGGKDNQKDKMAV
LTEEQLEKRIQMIV
EREKERQHQGQLPQ
LKAPPNIDAKSPHY
KHARRVHQSGDLGN

CNBG_6043
PSLHKVTPLGRAPA
LPEVQQAAQNGEID
QVDNTNEDVFWSHF
KYSSWIQDGYFRPN
SGTSKPGEGDFMMF

CNBG_4834
KEKLHVNVVVIGHV
HLIYKCGGIDKRTI
ALWKFETPKYQVTV
PGHRDFIKNMITGT
EFEAGISKDGQTRE
PISGWHGDNMLEET
NMPWYKGWTKETKS
AIEPPTRPTDKPLR
KIGGIGTVPVGRVE
GMVVKFAPTNVTTE
QIPEGLPGDNVGFN
IRRGNVCGDSKNDP
RTGKVMEAAPKFVK

CNBG_1355
SSTSLTGDIPTFYP
MPLMGFDGTGKKFK
RHEQKDQDRYWAQM
QIELGTPPQTFKVV
HSKYDSSQSSTYKA
TKEPGLAFAFGKFD
AYDTISVNHIVPPF
GGEAMFGGIDKSAY
HYVPVRRKGYWEVE
EKSWNGQYTVDCNT
PELSFTFEGRAYTL

CNBG_4851
IIKEGEVDIGGNPS
EEAAEALEEGAQQV
VVHSFRLQSTTFDK
VKTQLQESNPDRVA

* Did not have overlapping epitopes